



Clinical trial results:

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2017-002904-29 |
| Trial protocol | GB BE |
| Global end of trial date | 28 November 2022 |

Results information

| | |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Result version number | v2 (current) |
| This version publication date | 27 December 2023 |
| First version publication date | 26 October 2023 |
| Version creation reason | <ul style="list-style-type: none">• Correction of full data set Revisions made to align with revisions made to the ClinicalTrials.gov results summary to address NIH review comments. |

Trial information

Trial identification

| | |
|-----------------------|----------------|
| Sponsor protocol code | INCB 01158-203 |
|-----------------------|----------------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|------------------------------------------------------------------------|
| Sponsor organisation name | Incyte Corporation |
| Sponsor organisation address | 1801 Augustine Cutoff Drive, Wilmington, United States, |
| Public contact | Study Director, Incyte Corporation, 1 855-463-3463, medinfo@incyte.com |
| Scientific contact | Study Director, Incyte Corporation, 1 855-463-3463, medinfo@incyte.com |

Notes:

Paediatric regulatory details

| | |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|------------------------------------------------------|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 28 November 2022 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 28 November 2022 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

Phase 1: To assess the safety and tolerability and determine the recommended Phase 2 dose (RP2D) of INCB001158 in combination with chemotherapy

Phase 2: To evaluate the objective response rate (ORR) of INCB001158 in combination with chemotherapy

Protection of trial subjects:

This study was to be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and conducted in adherence to the study Protocol, Good Clinical Practices as defined in Title 21 of the United States Code of Federal Regulations Parts 11, 50, 54, 56, and 312, as well as International Conference on Harmonization Good Clinical Practice consolidated guidelines (E6) and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

| | |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment | 21 November 2017 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Belgium: 17 |
| Country: Number of subjects enrolled | United Kingdom: 37 |
| Country: Number of subjects enrolled | United States: 95 |
| Worldwide total number of subjects | 149 |
| EEA total number of subjects | 17 |

Notes:

Subjects enrolled per age group

| | |
|-------------------------------------------|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |

| | |
|---------------------------|----|
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 92 |
| From 65 to 84 years | 55 |
| 85 years and over | 2 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study was conducted at 11 study centers in the United States, the United Kingdom, and Belgium.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|--------------------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Phase 1: INCB001158 50 mg + mFOLFOX6 |

Arm description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 milligrams (mg) twice daily (BID) starting on Day 1 of each 28-day cycle. Participants also received intravenous modified FOLFOX6 (mFOLFOX6: oxaliplatin 85 mg/meters squared [m²], leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|----------------------------------------|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen

| | |
|----------------------------------------|-----------------------------------------------|
| Investigational medicinal product name | leucovorin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection, Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158

| | |
|----------------------------------------|------------------------|
| Investigational medicinal product name | 5-fluorouracil |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158

| | |
|----------------------------------------|---------------------------------------|
| Investigational medicinal product name | oxaliplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158

| | |
|------------------|--------------------------------------|
| Arm title | Phase 1: INCB001158 75 mg + mFOLFOX6 |
|------------------|--------------------------------------|

Arm description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|----------------------------------------|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen

| | |
|----------------------------------------|-----------------------------------------------|
| Investigational medicinal product name | leucovorin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection, Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158

| | |
|----------------------------------------|------------------------|
| Investigational medicinal product name | 5-fluorouracil |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158

| | |
|----------------------------------------|---------------------------------------|
| Investigational medicinal product name | oxaliplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158

| | |
|------------------|---------------------------------------|
| Arm title | Phase 1: INCB001158 100 mg + mFOLFOX6 |
|------------------|---------------------------------------|

Arm description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen | |
| Investigational medicinal product name | leucovorin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection, Solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158 | |
| Investigational medicinal product name | 5-fluorouracil |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158 | |
| Investigational medicinal product name | oxaliplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158 | |
| Arm title | Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin |
| Arm description: | |
| In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m ² and intravenous cisplatin 30 mg/m ² on Day 1 and Day 8 of each 28-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | gemcitabine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| administered on Days 1 and 8 of each 21-day cycle | |
| Investigational medicinal product name | cisplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| administered on Days 1 and 8 of each 21-day cycle | |
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |

| | |
|--------------------------|----------|
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen

| | |
|------------------|-----------------------------------------------------|
| Arm title | Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin |
|------------------|-----------------------------------------------------|

Arm description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and Day 8 of each 28-day cycle.

| | |
|----------------------------------------|---------------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | gemcitabine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Days 1 and 8 of each 21-day cycle

| | |
|----------------------------------------|---------------------------------------|
| Investigational medicinal product name | cisplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Days 1 and 8 of each 21-day cycle

| | |
|----------------------------------------|------------|
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen

| | |
|------------------|------------------------------------------------------|
| Arm title | Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin |
|------------------|------------------------------------------------------|

Arm description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and Day 8 of each 28-day cycle.

| | |
|----------------------------------------|---------------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | gemcitabine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Days 1 and 8 of each 21-day cycle

| | |
|----------------------------------------|---------------------------------------|
| Investigational medicinal product name | cisplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Dosage and administration details: | |
| administered on Days 1 and 8 of each 21-day cycle | |
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen | |
| Arm title | Phase 1: INCB001158 50 mg + Paclitaxel |
| Arm description: | |
| In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| administered on Days 1, 8, and 15 of each 28-day cycle | |
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen | |
| Arm title | Phase 1: INCB001158 75 mg + Paclitaxel |
| Arm description: | |
| In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: | |
| administered on Days 1, 8, and 15 of each 28-day cycle | |
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: | |
| Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen | |
| Arm title | Phase 1: INCB001158 100 mg + Paclitaxel |

Arm description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m² on Day 1, Day 8, and Day 15 of each 28-day cycle.

| | |
|----------------------------------------|---------------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Days 1, 8, and 15 of each 28-day cycle

| | |
|----------------------------------------|------------|
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen

| | |
|------------------|------------------------------------------------------------|
| Arm title | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) |
|------------------|------------------------------------------------------------|

Arm description:

In Phase 2, participants with microsatellite-stable-colorectal cancer (MSS-CRC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|----------------------------------------|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen

| | |
|----------------------------------------|-----------------------------------------------|
| Investigational medicinal product name | leucovorin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection, Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158

| | |
|----------------------------------------|------------------------|
| Investigational medicinal product name | 5-fluorouracil |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158

| | |
|----------------------------------------|-------------|
| Investigational medicinal product name | oxaliplatin |
| Investigational medicinal product code | |
| Other name | |

| | |
|--------------------------|---------------------------------------|
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158

| | |
|------------------|----------------------------------------------------------------|
| Arm title | Ph 2: INCB001158 100 mg+Gemcitabine+Cisplatin: BTC (Cohort B1) |
|------------------|----------------------------------------------------------------|

Arm description:

In Phase 2, participants with biliary tract cancer (BTC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 25 mg/m² on Day 1 and 8 of each 28-day cycle.

| | |
|----------------------------------------|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen

| | |
|----------------------------------------|---------------------------------------|
| Investigational medicinal product name | cisplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Days 1 and 8 of each 21-day cycle

| | |
|----------------------------------------|---------------------------------------|
| Investigational medicinal product name | gemcitabine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Days 1 and 8 of each 21-day cycle

| | |
|------------------|---------------------------------------------------------------|
| Arm title | Ph 2: INCB001158 100 mg+Gemcitabine+Cisplatin: OC (Cohort B2) |
|------------------|---------------------------------------------------------------|

Arm description:

In Phase 2, participants with ovarian cancer (OC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 750 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and 8 of each 28-day cycle.

| | |
|----------------------------------------|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen

| | |
|----------------------------------------|---------------------------------------|
| Investigational medicinal product name | cisplatin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|
| Dosage and administration details: administered on Days 1 and 8 of each 21-day cycle | |
| Investigational medicinal product name | gemcitabine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: administered on Days 1 and 8 of each 21-day cycle | |
| Arm title | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) |
| Arm description: In Phase 2, participants with gastroesophageal cancer (GC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: administered on Days 1, 8, and 15 of each 28-day cycle | |
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen | |
| Arm title | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) |
| Arm description: In Phase 2, participants with endometrial cancer (EC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Arm type | Experimental |
| Investigational medicinal product name | paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |
| Dosage and administration details: administered on Days 1, 8, and 15 of each 28-day cycle | |
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |
| Dosage and administration details: Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen | |
| Arm title | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) |

Arm description:

In Phase 2, participants with ovarian cancer (OC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m² on Day 1, Day 8, and Day 15 of each 28-day cycle.

| | |
|----------------------------------------|---------------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | paclitaxel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

administered on Days 1, 8, and 15 of each 28-day cycle

| | |
|----------------------------------------|------------|
| Investigational medicinal product name | INCB001158 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Phase 1: administered orally BID as 25 mg or 100 mg tablets; Phase 2: administered orally in 28- or 21-day cycles depending on the chemotherapy regimen

| Number of subjects in period 1 | Phase 1: INCB001158 50 mg + mFOLFOX6 | Phase 1: INCB001158 75 mg + mFOLFOX6 | Phase 1: INCB001158 100 mg + mFOLFOX6 |
|---------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------|
| Started | 8 | 6 | 6 |
| Completed | 0 | 0 | 0 |
| Not completed | 8 | 6 | 6 |
| Adverse event, serious fatal | 4 | 2 | 5 |
| Consent withdrawn by subject | 2 | 1 | 1 |
| Progressive Disease | 2 | - | - |
| Captured as "Other" in Database | - | 2 | - |
| Study Terminated by Sponsor | - | 1 | - |
| Lost to follow-up | - | - | - |

| Number of subjects in period 1 | Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin |
|---------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------|
| Started | 7 | 4 | 4 |
| Completed | 0 | 0 | 0 |
| Not completed | 7 | 4 | 4 |
| Adverse event, serious fatal | 4 | 3 | 4 |
| Consent withdrawn by subject | 2 | 1 | - |
| Progressive Disease | 1 | - | - |
| Captured as "Other" in Database | - | - | - |
| Study Terminated by Sponsor | - | - | - |
| Lost to follow-up | - | - | - |

| Number of subjects in period 1 | Phase 1: INCB001158 50 mg + Paclitaxel | Phase 1: INCB001158 75 mg + Paclitaxel | Phase 1: INCB001158 100 mg + Paclitaxel |
|---------------------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------------------|
| Started | 7 | 5 | 7 |
| Completed | 0 | 0 | 0 |
| Not completed | 7 | 5 | 7 |
| Adverse event, serious fatal | 5 | 4 | 3 |
| Consent withdrawn by subject | 1 | - | 1 |
| Progressive Disease | - | - | - |
| Captured as "Other" in Database | 1 | 1 | 1 |
| Study Terminated by Sponsor | - | - | 1 |
| Lost to follow-up | - | - | 1 |

| Number of subjects in period 1 | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | Ph 2: INCB001158 100 mg+Gemcitabine+Ci splatins: BTC (Cohort B1) | Ph 2: INCB001158 100 mg+Gemcitabine+Ci splatins: OC (Cohort B2) |
|---------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Started | 8 | 33 | 9 |
| Completed | 0 | 0 | 0 |
| Not completed | 8 | 33 | 9 |
| Adverse event, serious fatal | 5 | 20 | 6 |
| Consent withdrawn by subject | 1 | 4 | - |
| Progressive Disease | 1 | 1 | 1 |
| Captured as "Other" in Database | - | 1 | - |
| Study Terminated by Sponsor | - | 7 | 2 |
| Lost to follow-up | 1 | - | - |

| Number of subjects in period 1 | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) |
|---------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Started | 11 | 10 | 24 |
| Completed | 0 | 0 | 0 |
| Not completed | 11 | 10 | 24 |
| Adverse event, serious fatal | 7 | 6 | 17 |
| Consent withdrawn by subject | 1 | - | 1 |
| Progressive Disease | 2 | - | 1 |
| Captured as "Other" in Database | - | - | - |
| Study Terminated by Sponsor | 1 | 4 | 4 |
| Lost to follow-up | - | - | 1 |

Baseline characteristics

Reporting groups

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|
| Reporting group title | Phase 1: INCB001158 50 mg + mFOLFOX6 |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 milligrams (mg) twice daily (BID) starting on Day 1 of each 28-day cycle. Participants also received intravenous modified FOLFOX6 (mFOLFOX6: oxaliplatin 85 mg/meters squared [m ²], leucovorin 400 mg/m ² , and 5-fluorouracil 400 mg/m ² [bolus] and 2400 mg/m ² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158. | |
| Reporting group title | Phase 1: INCB001158 75 mg + mFOLFOX6 |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m ² , leucovorin 400 mg/m ² , and 5-fluorouracil 400 mg/m ² [bolus] and 2400 mg/m ² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158. | |
| Reporting group title | Phase 1: INCB001158 100 mg + mFOLFOX6 |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m ² , leucovorin 400 mg/m ² , and 5-fluorouracil 400 mg/m ² [bolus] and 2400 mg/m ² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158. | |
| Reporting group title | Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m ² and intravenous cisplatin 30 mg/m ² on Day 1 and Day 8 of each 28-day cycle. | |
| Reporting group title | Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m ² and intravenous cisplatin 30 mg/m ² on Day 1 and Day 8 of each 28-day cycle. | |
| Reporting group title | Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m ² and intravenous cisplatin 30 mg/m ² on Day 1 and Day 8 of each 28-day cycle. | |
| Reporting group title | Phase 1: INCB001158 50 mg + Paclitaxel |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Reporting group title | Phase 1: INCB001158 75 mg + Paclitaxel |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Reporting group title | Phase 1: INCB001158 100 mg + Paclitaxel |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Reporting group title | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) |
| Reporting group description: In Phase 2, participants with microsatellite-stable-colorectal cancer (MSS-CRC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous | |

mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| Reporting group title | Ph 2: INCB001158 100 mg+Gemcitabine+Cisplatin: BTC (Cohort B1) |
| Reporting group description: In Phase 2, participants with biliary tract cancer (BTC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m ² and intravenous cisplatin 25 mg/m ² on Day 1 and 8 of each 28-day cycle. | |
| Reporting group title | Ph 2: INCB001158 100 mg+Gemcitabine+Cisplatin: OC (Cohort B2) |
| Reporting group description: In Phase 2, participants with ovarian cancer (OC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 750 mg/m ² and intravenous cisplatin 30 mg/m ² on Day 1 and 8 of each 28-day cycle. | |
| Reporting group title | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) |
| Reporting group description: In Phase 2, participants with gastroesophageal cancer (GC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Reporting group title | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) |
| Reporting group description: In Phase 2, participants with endometrial cancer (EC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Reporting group title | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) |
| Reporting group description: In Phase 2, participants with ovarian cancer (OC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |

| Reporting group values | Phase 1: INCB001158 50 mg + mFOLFOX6 | Phase 1: INCB001158 75 mg + mFOLFOX6 | Phase 1: INCB001158 100 mg + mFOLFOX6 |
|-----------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------------|
| Number of subjects | 8 | 6 | 6 |
| Age categorical Units: Subjects | | | |
| Adults (18-64 years) | 6 | 4 | 2 |
| From 65-84 years | 2 | 2 | 4 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous Units: years | | | |
| arithmetic mean | 56.4 | 60.3 | 65.2 |
| standard deviation | ± 10.80 | ± 9.93 | ± 7.99 |
| Sex: Female, Male Units: participants | | | |
| Female | 3 | 4 | 3 |
| Male | 5 | 2 | 3 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| White | 2 | 6 | 6 |
| Black/African-American | 2 | 0 | 0 |
| Asian | 1 | 0 | 0 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| East Indian | 1 | 0 | 0 |

| | | | |
|-----------------------------------------|---|---|---|
| Not Provided/Specified | 1 | 0 | 0 |
| Black/Caribbean | 1 | 0 | 0 |
| Captured as Hispanic/Latino in Database | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 1 | 0 |
| Not Hispanic or Latino | 5 | 5 | 6 |
| Unknown or Not Reported | 3 | 0 | 0 |

| Reporting group values | Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin |
|-----------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------------|
| Number of subjects | 7 | 4 | 4 |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 4 | 3 | 3 |
| From 65-84 years | 3 | 0 | 1 |
| 85 years and over | 0 | 1 | 0 |
| Age Continuous | | | |
| Units: years | | | |
| arithmetic mean | 54.0 | 64.5 | 54.0 |
| standard deviation | ± 18.93 | ± 16.82 | ± 15.64 |
| Sex: Female, Male | | | |
| Units: participants | | | |
| Female | 3 | 2 | 3 |
| Male | 4 | 2 | 1 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| White | 6 | 3 | 4 |
| Black/African-American | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| East Indian | 0 | 0 | 0 |
| Not Provided/Specified | 0 | 0 | 0 |
| Black/Caribbean | 0 | 0 | 0 |
| Captured as Hispanic/Latino in Database | 1 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 1 | 0 | 0 |
| Not Hispanic or Latino | 6 | 4 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |

| Reporting group values | Phase 1: INCB001158 50 mg + Paclitaxel | Phase 1: INCB001158 75 mg + Paclitaxel | Phase 1: INCB001158 100 mg + Paclitaxel |
|------------------------|----------------------------------------------|----------------------------------------------|-----------------------------------------------|
| Number of subjects | 7 | 5 | 7 |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 4 | 5 | 4 |
| From 65-84 years | 2 | 0 | 3 |
| 85 years and over | 1 | 0 | 0 |

| | | | |
|-------------------------------------------------------------------------|-----------------|-----------------|----------------|
| Age Continuous Units: years arithmetic mean standard deviation | 62.0 ± 14.57 | 47.4 ± 10.29 | 61.4 ± 6.95 |
| Sex: Female, Male Units: participants | | | |
| Female | 5 | 4 | 5 |
| Male | 2 | 1 | 2 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| White | 7 | 5 | 5 |
| Black/African-American | 0 | 0 | 1 |
| Asian | 0 | 0 | 1 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| East Indian | 0 | 0 | 0 |
| Not Provided/Specified | 0 | 0 | 0 |
| Black/Caribbean | 0 | 0 | 0 |
| Captured as Hispanic/Latino in Database | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 7 | 5 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 |

| Reporting group values | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | Ph 2: INCB001158 100 mg+Gemcitabine+Ci splatina: BTC (Cohort B1) | Ph 2: INCB001158 100 mg+Gemcitabine+Ci splatina: OC (Cohort B2) |
|-------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Number of subjects | 8 | 33 | 9 |
| Age categorical Units: Subjects | | | |
| Adults (18-64 years) | 3 | 19 | 5 |
| From 65-84 years | 5 | 14 | 4 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous Units: years arithmetic mean standard deviation | 62.8 ± 11.26 | 59.3 ± 12.74 | 65.3 ± 8.87 |
| Sex: Female, Male Units: participants | | | |
| Female | 3 | 21 | 9 |
| Male | 5 | 12 | 0 |
| Race/Ethnicity, Customized Units: Subjects | | | |
| White | 7 | 31 | 8 |
| Black/African-American | 1 | 1 | 0 |
| Asian | 0 | 0 | 0 |
| American-Indian/Alaska Native | 0 | 0 | 1 |
| East Indian | 0 | 0 | 0 |
| Not Provided/Specified | 0 | 1 | 0 |
| Black/Caribbean | 0 | 0 | 0 |

| | | | |
|-----------------------------------------|---|----|---|
| Captured as Hispanic/Latino in Database | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 1 | 2 | 1 |
| Not Hispanic or Latino | 7 | 29 | 7 |
| Unknown or Not Reported | 0 | 2 | 1 |

| Reporting group values | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) |
|-----------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Number of subjects | 11 | 10 | 24 |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 8 | 7 | 15 |
| From 65-84 years | 3 | 3 | 9 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous | | | |
| Units: years | | | |
| arithmetic mean | 58.8 | 62.3 | 60.6 |
| standard deviation | ± 11.90 | ± 9.29 | ± 9.04 |
| Sex: Female, Male | | | |
| Units: participants | | | |
| Female | 4 | 10 | 24 |
| Male | 7 | 0 | 0 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| White | 8 | 8 | 23 |
| Black/African-American | 0 | 1 | 0 |
| Asian | 2 | 1 | 1 |
| American-Indian/Alaska Native | 0 | 0 | 0 |
| East Indian | 0 | 0 | 0 |
| Not Provided/Specified | 1 | 0 | 0 |
| Black/Caribbean | 0 | 0 | 0 |
| Captured as Hispanic/Latino in Database | 0 | 0 | 0 |
| Ethnicity (NIH/OMB) | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 10 | 23 |
| Unknown or Not Reported | 0 | 0 | 1 |

| Reporting group values | Total | | |
|------------------------|-------|--|--|
| Number of subjects | 149 | | |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-64 years) | 92 | | |
| From 65-84 years | 55 | | |
| 85 years and over | 2 | | |
| Age Continuous | | | |
| Units: years | | | |
| arithmetic mean | | | |

| | | | |
|--------------------|---|--|--|
| standard deviation | - | | |
|--------------------|---|--|--|

| | | | |
|-----------------------------------------------|-----|--|--|
| Sex: Female, Male Units: participants | | | |
| Female | 103 | | |
| Male | 46 | | |
| Race/Ethnicity, Customized Units: Subjects | | | |
| White | 129 | | |
| Black/African-American | 6 | | |
| Asian | 7 | | |
| American-Indian/Alaska Native | 1 | | |
| East Indian | 1 | | |
| Not Provided/Specified | 3 | | |
| Black/Caribbean | 1 | | |
| Captured as Hispanic/Latino in Database | 1 | | |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | 6 | | |
| Not Hispanic or Latino | 136 | | |
| Unknown or Not Reported | 7 | | |

End points

End points reporting groups

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------|
| Reporting group title | Phase 1: INCB001158 50 mg + mFOLFOX6 |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 milligrams (mg) twice daily (BID) starting on Day 1 of each 28-day cycle. Participants also received intravenous modified FOLFOX6 (mFOLFOX6: oxaliplatin 85 mg/meters squared [m ²], leucovorin 400 mg/m ² , and 5-fluorouracil 400 mg/m ² [bolus] and 2400 mg/m ² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158. | |
| Reporting group title | Phase 1: INCB001158 75 mg + mFOLFOX6 |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m ² , leucovorin 400 mg/m ² , and 5-fluorouracil 400 mg/m ² [bolus] and 2400 mg/m ² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158. | |
| Reporting group title | Phase 1: INCB001158 100 mg + mFOLFOX6 |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m ² , leucovorin 400 mg/m ² , and 5-fluorouracil 400 mg/m ² [bolus] and 2400 mg/m ² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158. | |
| Reporting group title | Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m ² and intravenous cisplatin 30 mg/m ² on Day 1 and Day 8 of each 28-day cycle. | |
| Reporting group title | Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m ² and intravenous cisplatin 30 mg/m ² on Day 1 and Day 8 of each 28-day cycle. | |
| Reporting group title | Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m ² and intravenous cisplatin 30 mg/m ² on Day 1 and Day 8 of each 28-day cycle. | |
| Reporting group title | Phase 1: INCB001158 50 mg + Paclitaxel |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Reporting group title | Phase 1: INCB001158 75 mg + Paclitaxel |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Reporting group title | Phase 1: INCB001158 100 mg + Paclitaxel |
| Reporting group description: In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m ² on Day 1, Day 8, and Day 15 of each 28-day cycle. | |
| Reporting group title | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) |
| Reporting group description: In Phase 2, participants with microsatellite-stable-colorectal cancer (MSS-CRC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous | |

mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|-----------------------|----------------------------------------------------------------|
| Reporting group title | Ph 2: INCB001158 100 mg+Gemcitabine+Cisplatin: BTC (Cohort B1) |
|-----------------------|----------------------------------------------------------------|

Reporting group description:

In Phase 2, participants with biliary tract cancer (BTC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 25 mg/m² on Day 1 and 8 of each 28-day cycle.

| | |
|-----------------------|---------------------------------------------------------------|
| Reporting group title | Ph 2: INCB001158 100 mg+Gemcitabine+Cisplatin: OC (Cohort B2) |
|-----------------------|---------------------------------------------------------------|

Reporting group description:

In Phase 2, participants with ovarian cancer (OC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 750 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and 8 of each 28-day cycle.

| | |
|-----------------------|---------------------------------------------------------|
| Reporting group title | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) |
|-----------------------|---------------------------------------------------------|

Reporting group description:

In Phase 2, participants with gastroesophageal cancer (GC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m² on Day 1, Day 8, and Day 15 of each 28-day cycle.

| | |
|-----------------------|---------------------------------------------------------|
| Reporting group title | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) |
|-----------------------|---------------------------------------------------------|

Reporting group description:

In Phase 2, participants with endometrial cancer (EC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m² on Day 1, Day 8, and Day 15 of each 28-day cycle.

| | |
|-----------------------|---------------------------------------------------------|
| Reporting group title | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) |
|-----------------------|---------------------------------------------------------|

Reporting group description:

In Phase 2, participants with ovarian cancer (OC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous paclitaxel 80 mg/m² on Day 1, Day 8, and Day 15 of each 28-day cycle.

| | |
|----------------------------|--------------------------------------------------|
| Subject analysis set title | Phase 1 and Phase 2: INCB001158 50 mg + mFOLFOX6 |
|----------------------------|--------------------------------------------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and MSS-CRC (Phase 2) also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|----------------------------|--------------------------------------------------|
| Subject analysis set title | Phase 1 and Phase 2: INCB001158 75 mg + mFOLFOX6 |
|----------------------------|--------------------------------------------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. In Phases 1 and 2, participants with advanced or solid metastatic tumors (Phase 1) and MSS-CRC (Phase 2) also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|----------------------------|---------------------------------------------------|
| Subject analysis set title | Phase 1 and Phase 2: INCB001158 100 mg + mFOLFOX6 |
|----------------------------|---------------------------------------------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and MSS-CRC (Phase 2) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|----------------------------|-------------------------------------------------------------|
| Subject analysis set title | Phase 1 and Phase 2: INCB001158 50 mg+Gemcitabine+Cisplatin |
|----------------------------|-------------------------------------------------------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000

mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and Day 8 of each 28-day cycle. In Phase 2, participants with BTC received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 25 mg/m² on Day 1 and 8 of each 28-day cycle, and participants with OC received intravenous gemcitabine 750 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and 8 of each 28-day cycle.

| | |
|----------------------------|-------------------------------------------------------------|
| Subject analysis set title | Phase 1 and Phase 2: INCB001158 75 mg+Gemcitabine+Cisplatin |
| Subject analysis set type | Full analysis |

Subject analysis set description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and Day 8 of each 28-day cycle. In Phase 2, participants with BTC received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 25 mg/m² on Day 1 and 8 of each 28-day cycle, and participants with OC received intravenous gemcitabine 750 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and 8 of each 28-day cycle.

| | |
|----------------------------|--------------------------------------------------------------|
| Subject analysis set title | Phase 1 and Phase 2: INCB001158 100 mg+Gemcitabine+Cisplatin |
| Subject analysis set type | Full analysis |

Subject analysis set description:

In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and with BTC or OC (Phase 2) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. In Phase 1, participants also received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and Day 8 of each 28-day cycle. In Phase 2, participants with BTC received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 25 mg/m² on Day 1 and 8 of each 28-day cycle, and participants with OC received intravenous gemcitabine 750 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and 8 of each 28-day cycle.

| | |
|----------------------------|----------------------------------------------------|
| Subject analysis set title | Phase 1 and Phase 2: INCB001158 50 mg + Paclitaxel |
| Subject analysis set type | Full analysis |

Subject analysis set description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and with GC, EC, or OC (Phase 2) received intravenous paclitaxel 80 mg/m² on Day 1, Day 8, and Day 15 of each 28-day cycle.

| | |
|----------------------------|----------------------------------------------------|
| Subject analysis set title | Phase 1 and Phase 2: INCB001158 75 mg + Paclitaxel |
| Subject analysis set type | Full analysis |

Subject analysis set description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and with GC, EC, or OC (Phase 2) received intravenous paclitaxel 80 mg/m² on Day 1, Day 8, and Day 15 of each 28-day cycle.

| | |
|----------------------------|-----------------------------------------------------|
| Subject analysis set title | Phase 1 and Phase 2: INCB001158 100 mg + Paclitaxel |
| Subject analysis set type | Full analysis |

Subject analysis set description:

In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and GC, EC, or OC (Phase 2) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants with advanced or metastatic solid tumors (Phase 1) and with GC, EC, or OC (Phase 2) also received intravenous paclitaxel 80 mg/m² on Day 1, Day 8, and Day 15 of each 28-day cycle.

| | |
|----------------------------|--------------------------|
| Subject analysis set title | All Phase 1 Participants |
| Subject analysis set type | Full analysis |

Subject analysis set description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50, 75, or 100 mg BID plus intravenous modified FOLFOX6, intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 30 mg/m², or intravenous paclitaxel 80 mg/m².

| | |
|----------------------------|--------------------------------------------------------------|
| Subject analysis set title | Phase 1 and Phase 2: INCB001158 75 mg + mFOLFOX6 (Cohort B1) |
| Subject analysis set type | Full analysis |

Subject analysis set description:

In Phase 2, for Pharmacokinetic (PK) analysis, participants with biliary tract cancer (BTC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 25 mg/m² on Day 1 and 8 of each 28-day cycle.

| | |
|----------------------------|--------------------------------------------------------------|
| Subject analysis set title | Phase 1 and Phase 2: INCB001158 75 mg + mFOLFOX6 (Cohort B1) |
|----------------------------|--------------------------------------------------------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

In Phase 2, for PK analysis, participants with biliary tract cancer (BTC) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 25 mg/m² on Day 1 and 8 of each 28-day cycle.

Primary: Phases 1 and 2: Number of participants with any treatment-emergent adverse event (TEAE)

| | |
|-----------------|--------------------------------------------------------------------------------------------------------|
| End point title | Phases 1 and 2: Number of participants with any treatment-emergent adverse event (TEAE) ^[1] |
|-----------------|--------------------------------------------------------------------------------------------------------|

End point description:

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug. As pre-defined in the Statistical Analysis Plan, data analysis was conducted based on treatment group and dose level, regardless of study phase, because the safety profile was expected to be generally uniform across tumor types.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

up to 1385 days

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted for this endpoint.

| End point values | Phase 1 and Phase 2: INCB001158 50 mg + mFOLFOX6 | Phase 1 and Phase 2: INCB001158 75 mg + mFOLFOX6 | Phase 1 and Phase 2: INCB001158 100 mg + mFOLFOX6 | Phase 1 and Phase 2: INCB001158 50 mg+Gemcitabine+Cisplatin |
|-----------------------------|--------------------------------------------------|--------------------------------------------------|---------------------------------------------------|-------------------------------------------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 8 | 6 | 14 | 7 |
| Units: participants | 8 | 6 | 13 | 7 |

| End point values | Phase 1 and Phase 2: INCB001158 75 mg+Gemcitabine+Cisplatin | Phase 1 and Phase 2: INCB001158 100 mg+Gemcitabine+Cisplatin | Phase 1 and Phase 2: INCB001158 50 mg + Paclitaxel | Phase 1 and Phase 2: INCB001158 75 mg + Paclitaxel |
|-----------------------------|-------------------------------------------------------------|--------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | Subject analysis set |
| Number of subjects analysed | 4 | 46 | 7 | 5 |
| Units: participants | 4 | 46 | 7 | 5 |

| End point values | Phase 1 and Phase 2: INCB001158 100 mg + Paclitaxel | | | |
|------------------|-----------------------------------------------------|--|--|--|
|------------------|-----------------------------------------------------|--|--|--|

| | | | | |
|-----------------------------|----------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 52 | | | |
| Units: participants | 51 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Phase 1: Number of participants with any dose-limiting toxicity (DLT)

| | |
|-----------------|-----------------------------------------------------------------------------------------|
| End point title | Phase 1: Number of participants with any dose-limiting toxicity (DLT) ^{[2][3]} |
|-----------------|-----------------------------------------------------------------------------------------|

End point description:

A DLT was defined as the occurrence of any protocol-defined toxicity occurring up to and including Day 28, except those with a clear alternative explanation (e.g., disease progression) or transient (≤ 72 hours) abnormal laboratory values without associated clinically significant signs or symptoms based on investigator determination. All DLTs were assessed by the investigator using Common Terminology Criteria for Adverse Events (CTCAE) v4.03 criteria.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

up to Day 28

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted for this endpoint.

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

| End point values | Phase 1: INCB001158 50 mg + mFOLFOX6 | Phase 1: INCB001158 75 mg + mFOLFOX6 | Phase 1: INCB001158 100 mg + mFOLFOX6 | Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin |
|-----------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------|-----------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 8 | 6 | 6 | 7 |
| Units: participants | 0 | 0 | 0 | 1 |

| End point values | Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 50 mg + Paclitaxel | Phase 1: INCB001158 75 mg + Paclitaxel |
|-----------------------------|-----------------------------------------------------------------|------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 4 | 7 | 5 |
| Units: participants | 0 | 0 | 0 | 0 |

| End point values | Phase 1: INCB001158 100 mg + | | | |
|------------------|------------------------------------|--|--|--|
|------------------|------------------------------------|--|--|--|

| | | | | |
|-----------------------------|-----------------|--|--|--|
| | Paclitaxel | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 7 | | | |
| Units: participants | 0 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2: Objective Response Rate (ORR)

| | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| End point title | Phase 2: Objective Response Rate (ORR) ^{[4][5]} |
| End point description: | |
| <p>ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), as determined by investigator assessment of radiographic disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Analysis was conducted by cohort (tumor type) in Phase 2 because different tumor types could have different response criteria or different background response rates.</p> | |
| End point type | Primary |
| End point timeframe: | |
| up to 1385 days | |

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted for this endpoint.

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

| End point values | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: BTC (Cohort B1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: OC (Cohort B2) | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) |
|-----------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 8 | 33 | 9 | 11 |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 0.0 (0.0 to 36.9) | 24.2 (11.1 to 42.3) | 22.2 (2.8 to 60.0) | 9.1 (0.2 to 41.3) |

| End point values | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) | | |
|-----------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 24 | | |

| | | | | |
|-----------------------------------|--------------------|--------------------|--|--|
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 30.0 (6.7 to 65.2) | 16.7 (4.7 to 37.4) | | |

Statistical analyses

No statistical analyses for this end point

Primary: Recommended Phase 2 dose (RP2D) of INCB001158 when given in combination with each chemotherapy regimen

| | |
|-----------------|-----------------------------------------------------------------------------------------------------------------------|
| End point title | Recommended Phase 2 dose (RP2D) of INCB001158 when given in combination with each chemotherapy regimen ^[6] |
|-----------------|-----------------------------------------------------------------------------------------------------------------------|

End point description:

The RP2D of the combination of INCB001158 and chemotherapy in 21-day (for gemcitabine/cisplatin) or 28-day (for mFOLFOX6 or paclitaxel) treatment cycles in participants with advanced or metastatic solid tumors was determined. After the dose escalation was completed, the INCB001158 dose level that was pharmacologically active and tolerable in combination with each chemotherapy regimen (i.e., maximum tolerated dose or lower) was determined to be the RP2D. The RP2D was then further assessed in tumor expansion cohorts in Phase 2.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

up to Day 580

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted for this endpoint.

| | | | | |
|-----------------------------|--------------------------|--|--|--|
| End point values | All Phase 1 Participants | | | |
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 54 | | | |
| Units: milligrams | 100 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1: ORR

| | |
|-----------------|-----------------------------|
| End point title | Phase 1: ORR ^[7] |
|-----------------|-----------------------------|

End point description:

ORR was defined as the percentage of participants with a confirmed best overall response of CR or PR, as determined by investigator assessment of radiographic disease as per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the Baseline sum diameters, no new lesions, and no progression of non-target lesions.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 580 days

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Statistical analysis was not conducted for this endpoint.

| End point values | Phase 1: INCB001158 50 mg + mFOLFOX6 | Phase 1: INCB001158 75 mg + mFOLFOX6 | Phase 1: INCB001158 100 mg + mFOLFOX6 | Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin |
|-----------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------|-----------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 8 | 6 | 6 | 7 |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 12.5 (0.3 to 52.7) | 0.0 (0.0 to 45.9) | 0.0 (0.0 to 45.9) | 0.0 (0.0 to 41.0) |

| End point values | Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 50 mg + Paclitaxel | Phase 1: INCB001158 75 mg + Paclitaxel |
|-----------------------------------|-----------------------------------------------------------------|------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 4 | 7 | 5 |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 25.0 (0.6 to 80.6) | 0.0 (0.0 to 60.2) | 14.3 (0.4 to 57.9) | 0.0 (0.0 to 52.2) |

| End point values | Phase 1: INCB001158 100 mg + Paclitaxel | | | |
|-----------------------------------|--------------------------------------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 7 | | | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 28.6 (3.7 to 71.0) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Phases 1 and 2: Duration of Response

| | |
|-----------------|--------------------------------------|
| End point title | Phases 1 and 2: Duration of Response |
|-----------------|--------------------------------------|

End point description:

DOR was defined as the time from initial objective response (CR or PR) (as determined by investigator assessment of radiographic disease assessment per RECIST v1.1) until the earliest date of disease progression or death due to any cause, if it occurred sooner than disease progression. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target

lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. 9999=the upper limit of the confidence interval was not estimable because too few participants had disease progression or died. The Kaplan Meier estimation method on a sample size of less than 5 responders is not valid.

| | |
|----------------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: up to 368 days | |

| End point values | Phase 1: INCB001158 50 mg + mFOLFOX6 | Phase 1: INCB001158 75 mg + mFOLFOX6 | Phase 1: INCB001158 100 mg + mFOLFOX6 | Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin |
|----------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------|-----------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[8] | 0 ^[9] | 0 ^[10] | 0 ^[11] |
| Units: months | | | | |
| median (confidence interval 95%) | (to) | (to) | (to) | (to) |

Notes:

[8] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

[9] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

[10] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

[11] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

| End point values | Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 50 mg + Paclitaxel | Phase 1: INCB001158 75 mg + Paclitaxel |
|----------------------------------|-----------------------------------------------------------------|------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[12] | 0 ^[13] | 0 ^[14] | 0 ^[15] |
| Units: months | | | | |
| median (confidence interval 95%) | (to) | (to) | (to) | (to) |

Notes:

[12] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

[13] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

[14] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

[15] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

| End point values | Phase 1: INCB001158 100 mg + Paclitaxel | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: BTC (Cohort B1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: OC (Cohort B2) |
|----------------------------------|--------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 0 ^[16] | 0 ^[17] | 8 | 0 ^[18] |
| Units: months | | | | |
| median (confidence interval 95%) | (to) | (to) | 5.8 (4.1 to 9999) | (to) |

Notes:

[16] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

[17] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

[18] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

| End point values | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) | |
|----------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 0 ^[19] | 0 ^[20] | 0 ^[21] | |
| Units: months | | | | |
| median (confidence interval 95%) | (to) | (to) | (to) | |

Notes:

[19] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

[20] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

[21] - Duration of response was analyzed in cohorts with >5 objective responders (CR or PR).

Statistical analyses

No statistical analyses for this end point

Secondary: Phases 1 and 2: Disease Control Rate

| | |
|-----------------|--------------------------------------|
| End point title | Phases 1 and 2: Disease Control Rate |
|-----------------|--------------------------------------|

End point description:

DCR was defined as the percentage of participants with an overall response of CR, PR, or stable disease (SD), as determined by investigator assessment of radiographic disease as per RECIST v1.1, for at least 8 weeks. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to <10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 1385 days

| End point values | Phase 1: INCB001158 50 mg + mFOLFOX6 | Phase 1: INCB001158 75 mg + mFOLFOX6 | Phase 1: INCB001158 100 mg + mFOLFOX6 | Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin |
|-----------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------|-----------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 8 | 6 | 6 | 7 |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 62.5 (24.5 to 91.5) | 83.3 (35.9 to 99.6) | 16.7 (0.4 to 64.1) | 57.1 (18.4 to 90.1) |

| End point values | Phase 1: INCB001158 75 mg + Gemcitabine + | Phase 1: INCB001158 100 mg + Gemcitabine + | Phase 1: INCB001158 50 mg + Paclitaxel | Phase 1: INCB001158 75 mg + Paclitaxel |
|------------------|----------------------------------------------------|-----------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|------------------|----------------------------------------------------|-----------------------------------------------------|-------------------------------------------------|-------------------------------------------------|

| | Cisplatin | Cisplatin | | |
|-----------------------------------|---------------------|-----------------------|--------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 4 | 7 | 5 |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 75.0 (19.4 to 99.4) | 100.0 (39.8 to 100.0) | 42.9 (9.9 to 81.6) | 60.0 (14.7 to 94.7) |

| End point values | Phase 1: INCB001158 100 mg + Paclitaxel | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: BTC (Cohort B1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: OC (Cohort B2) |
|-----------------------------------|--------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 7 | 8 | 33 | 9 |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 85.7 (42.1 to 99.6) | 100.0 (63.1 to 100.0) | 66.7 (48.2 to 82.0) | 88.9 (51.8 to 99.7) |

| End point values | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) | |
|-----------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 10 | 24 | |
| Units: percentage of participants | | | | |
| number (confidence interval 95%) | 54.5 (23.4 to 83.3) | 80.0 (44.4 to 97.5) | 66.7 (44.7 to 84.4) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Phases 1 and 2: Progression-free Survival

| | |
|-----------------|-------------------------------------------|
| End point title | Phases 1 and 2: Progression-free Survival |
|-----------------|-------------------------------------------|

End point description:

According to RECIST 1.1, PFS was defined as the length of time from the date of the first dose study of drug until the earliest date of disease progression, as determined by investigator assessment of radiographic disease per RECIST v1.1, or death due to any cause, if it occurred sooner than progression. -9999, 9999=the upper and lower limits of the confidence interval were not estimable because too few participants had disease progression or died.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 1385 days

| End point values | Phase 1: INCB001158 50 mg + mFOLFOX6 | Phase 1: INCB001158 75 mg + mFOLFOX6 | Phase 1: INCB001158 100 mg + mFOLFOX6 | Phase 1: INCB001158 50 mg + Gemcitabine + Cisplatin |
|----------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------------|-----------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 8 | 6 | 6 | 7 |
| Units: months | | | | |
| median (confidence interval 95%) | 3.7 (1.8 to 3.9) | 6.6 (1.7 to 9999) | 1.7 (1.6 to 9999) | 3.9 (0.6 to 9999) |

| End point values | Phase 1: INCB001158 75 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 100 mg + Gemcitabine + Cisplatin | Phase 1: INCB001158 50 mg + Paclitaxel | Phase 1: INCB001158 75 mg + Paclitaxel |
|----------------------------------|-----------------------------------------------------------------|------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 4 | 4 | 7 | 5 |
| Units: months | | | | |
| median (confidence interval 95%) | 5.3 (-9999 to 9999) | 6.4 (3.7 to 9999) | 3.9 (0.8 to 9999) | 3.7 (1.5 to 9999) |

| End point values | Phase 1: INCB001158 100 mg + Paclitaxel | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: BTC (Cohort B1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: OC (Cohort B2) |
|----------------------------------|--------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 7 | 8 | 33 | 9 |
| Units: months | | | | |
| median (confidence interval 95%) | 11.8 (1.7 to 16.1) | 3.7 (2.8 to 9999) | 8.5 (5.7 to 10.1) | 7.8 (2.2 to 9999) |

| End point values | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) | |
|----------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 11 | 10 | 24 | |
| Units: months | | | | |
| median (confidence interval 95%) | 3.5 (1.7 to 9999) | 7.1 (3.5 to 11.1) | 3.7 (2.4 to 4.9) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Cmin of INCB001158 in participants treated with INCB001158 in combination with chemotherapy on Cycle 2 Day 1 following repeated dose administration

| | |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Cmin of INCB001158 in participants treated with INCB001158 in combination with chemotherapy on Cycle 2 Day 1 following repeated dose administration ^[22] |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Cmin was defined as the minimum observed plasma concentration over the dose interval. Extensive sample collection was used for the first 12 participants enrolled in each chemotherapy regimen. Sparse sample collection was used for the 13th participant enrolled and onward.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 of Cycle 2: predose; 0.5, 1, 2, 4, 6, and 8-10 hours post-dose for extensive sample collection.
Day 1 of Cycle 2: predose; 1 and 4 hours post-dose for sparse sample collection

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

| End point values | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: BTC (Cohort B1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: OC (Cohort B2) | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) |
|-----------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 7 ^[23] | 17 ^[24] | 8 ^[25] | 8 ^[26] |
| Units: nanograms per milliliter (ng/mL) | | | | |
| geometric mean (geometric coefficient of variation) | 747 (± 35.7) | 407 (± 407) | 268 (± 888) | 542 (± 102) |

Notes:

[23] - Only participants with available data were analyzed.

[24] - Only participants with available data were analyzed.

[25] - Only participants with available data were analyzed.

[26] - Only participants with available data were analyzed.

| End point values | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) | | |
|-----------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 5 ^[27] | 13 ^[28] | | |
| Units: nanograms per milliliter (ng/mL) | | | | |
| geometric mean (geometric coefficient of variation) | 1020 (± 27.2) | 633 (± 131) | | |

of variation)

Notes:

[27] - Only participants with available data were analyzed.

[28] - Only participants with available data were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: Cmax of INCB001158 in participants treated with INCB001158 in combination with chemotherapy following the first dose on Cycle 1 Day 1 and on Cycle 2 Day 1 following repeated dose administration

| | |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Cmax of INCB001158 in participants treated with INCB001158 in combination with chemotherapy following the first dose on Cycle 1 Day 1 and on Cycle 2 Day 1 following repeated dose administration ^[29] |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Cmax was defined as the maximum observed plasma concentration over the dose interval. Extensive sample collection was used for the first 12 participants enrolled in each chemotherapy regimen. Sparse sample collection was used for the 13th participant enrolled and onward.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 of Cycles 1 and 2: predose; 0.5, 1, 2, 4, 6, and 8-10 hours post-dose for extensive sample collection. Day 1 of Cycles 1 and 2: predose; 1 and 4 hours post-dose for sparse sample collection

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

| End point values | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: BTC (Cohort B1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: OC (Cohort B2) | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) |
|-----------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 8 ^[30] | 18 ^[31] | 9 ^[32] | 10 ^[33] |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 1 Day 1, n=8, 18, 9, 10, 6, 15 | 1290 (± 16.4) | 1350 (± 35.2) | 2160 (± 22.3) | 1100 (± 68.0) |
| Cycle 2 Day 1, n=7, 17, 8, 8, 5, 13 | 1960 (± 12.6) | 1860 (± 46.7) | 2250 (± 26.4) | 1600 (± 22.0) |

Notes:

[30] - Only participants with available data were analyzed.

[31] - Only participants with available data were analyzed.

[32] - Only participants with available data were analyzed.

[33] - Only participants with available data were analyzed.

| End point values | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) | | |
|------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
|------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--|--|

| | | | | |
|-----------------------------------------------------|-------------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 6 ^[34] | 15 ^[35] | | |
| Units: ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 1 Day 1, n=8, 18, 9, 10, 6, 15 | 1760 (± 17.2) | 1640 (± 23.2) | | |
| Cycle 2 Day 1, n=7, 17, 8, 8, 5, 13 | 2390 (± 11.4) | 2100 (± 24.6) | | |

Notes:

[34] - Only participants with available data were analyzed.

[35] - Only participants with available data were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: tmax of INCB001158 in participants treated with INCB001158 in combination with chemotherapy following the first dose on Cycle 1 Day 1 and on Cycle 2 Day 1 following repeated dose administration

| | |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | tmax of INCB001158 in participants treated with INCB001158 in combination with chemotherapy following the first dose on Cycle 1 Day 1 and on Cycle 2 Day 1 following repeated dose administration ^[36] |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

tmax was defined as the time to the maximum concentration. Extensive sample collection was used for the first 12 participants enrolled in each chemotherapy regimen. Sparse sample collection was used for the 13th participant enrolled and onward.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 of Cycles 1 and 2: predose; 0.5, 1, 2, 4, 6, and 8-10 hours post-dose for extensive sample collection. Day 1 of Cycles 1 and 2: predose; 1 and 4 hours post-dose for sparse sample collection

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

| | | | | |
|--------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------|
| End point values | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: BTC (Cohort B1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: OC (Cohort B2) | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) |
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 8 ^[37] | 18 ^[38] | 9 ^[39] | 10 ^[40] |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Cycle 1 Day 1, n=8, 18, 9, 10, 6, 15 | 4.13 (2.00 to 6.10) | 4.07 (1.97 to 7.53) | 4.08 (3.67 to 6.00) | 5.05 (2.25 to 7.50) |
| Cycle 2 Day 1, n=7, 17, 8, 8, 5, 13 | 4.00 (1.80 to 7.50) | 4.00 (0.983 to 7.53) | 4.06 (2.03 to 6.02) | 4.13 (1.92 to 7.53) |

Notes:

[37] - Only participants with available data were analyzed.

[38] - Only participants with available data were analyzed.

[39] - Only participants with available data were analyzed.

[40] - Only participants with available data were analyzed.

| | | | | |
|--------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| End point values | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 6 ^[41] | 15 ^[42] | | |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Cycle 1 Day 1, n=8, 18, 9, 10, 6, 15 | 4.09 (2.00 to 6.17) | 3.97 (1.78 to 6.08) | | |
| Cycle 2 Day 1, n=7, 17, 8, 8, 5, 13 | 3.85 (3.77 to 3.92) | 3.95 (2.03 to 6.00) | | |

Notes:

[41] - Only participants with available data were analyzed.

[42] - Only participants with available data were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: AUC0-t of INCB001158 in participants treated with INCB001158 in combination with chemotherapy following the first dose on Cycle 1 Day 1 and on Cycle 2 Day 1 following repeated dose administration

| | |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | AUC0-t of INCB001158 in participants treated with INCB001158 in combination with chemotherapy following the first dose on Cycle 1 Day 1 and on Cycle 2 Day 1 following repeated dose administration ^[43] |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

AUC0-t was defined as the area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t. Extensive sample collection was used for the first 12 participants enrolled in each chemotherapy regimen. Sparse sample collection was used for the 13th participant enrolled and onward.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 of Cycles 1 and 2: predose; 0.5, 1, 2, 4, 6, and 8-10 hours post-dose for extensive sample collection. Day 1 of Cycles 1 and 2: predose; 1 and 4 hours post-dose for sparse sample collection

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

| | | | | |
|-----------------------------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------|
| End point values | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: BTC (Cohort B1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: OC (Cohort B2) | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) |
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 8 ^[44] | 18 ^[45] | 9 ^[46] | 10 ^[47] |
| Units: hours x ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 1 Day 1, n=8, 18, 9, 10, 6, 15 | 6910 (± 17.6) | 7240 (± 32.9) | 10600 (± 18.9) | 4680 (± 134) |
| Cycle 2 Day 1, n=7, 17, 8, 8, 5, 13 | 11000 (± 21.1) | 10600 (± 55.3) | 12200 (± 34.4) | 10000 (± 18.4) |

Notes:

- [44] - Only participants with available data were analyzed.
 [45] - Only participants with available data were analyzed.
 [46] - Only participants with available data were analyzed.
 [47] - Only participants with available data were analyzed.

| End point values | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) | | |
|-----------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 6 ^[48] | 15 ^[49] | | |
| Units: hours x ng/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Cycle 1 Day 1, n=8, 18, 9, 10, 6, 15 | 9290 (± 33.2) | 8840 (± 24.7) | | |
| Cycle 2 Day 1, n=7, 17, 8, 8, 5, 13 | 14400 (± 13.7) | 12800 (± 30.3) | | |

Notes:

- [48] - Only participants with available data were analyzed.
 [49] - Only participants with available data were analyzed.

Statistical analyses

No statistical analyses for this end point

Secondary: tlast of INCB001158 in participants treated with INCB001158 in combination with chemotherapy following the first dose on Cycle 1 Day 1 and on Cycle 2 Day 1 following repeated dose administration

| | |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | tlast of INCB001158 in participants treated with INCB001158 in combination with chemotherapy following the first dose on Cycle 1 Day 1 and on Cycle 2 Day 1 following repeated dose administration ^[50] |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

tlast was defined as the time of the last sample collected from which a concentration was measured. Extensive sample collection was used for the first 12 participants enrolled in each chemotherapy regimen. Sparse sample collection was used for the 13th participant enrolled and onward.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 of Cycles 1 and 2: predose; 0.5, 1, 2, 4, 6, and 8-10 hours post-dose for extensive sample collection. Day 1 of Cycles 1 and 2: predose; 1 and 4 hours post-dose for sparse sample collection

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

| End point values | Phase 2: INCB001158 100 mg + mFOLFOX6: MSS-CRC (Cohort A1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: BTC (Cohort B1) | Ph 2: INCB001158 100 mg+Gemcitabi ne+Cisplatin: OC (Cohort B2) | Phase 2: INCB001158 100 mg + Paclitaxel: GC (Cohort C1) |
|-------------------------------|---------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 8 ^[51] | 18 ^[52] | 9 ^[53] | 10 ^[54] |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |

| | | | | |
|--------------------------------------|---------------------|---------------------|---------------------|---------------------|
| Cycle 1 Day 1, n=8, 18, 9, 10, 6, 15 | 7.53 (7.47 to 8.00) | 7.73 (6.00 to 8.42) | 7.53 (7.50 to 8.05) | 7.50 (3.50 to 8.08) |
| Cycle 2 Day 1, n=7, 17, 8, 8, 5, 13 | 7.50 (6.00 to 7.57) | 7.58 (7.50 to 8.38) | 7.60 (7.50 to 8.25) | 7.57 (7.50 to 8.00) |

Notes:

[51] - Only participants with available data were analyzed.

[52] - Only participants with available data were analyzed.

[53] - Only participants with available data were analyzed.

[54] - Only participants with available data were analyzed.

| End point values | Phase 2: INCB001158 100 mg + Paclitaxel: EC (Cohort C2) | Phase 2: INCB001158 100 mg + Paclitaxel: OC (Cohort C3) | | |
|--------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 6 ^[55] | 15 ^[56] | | |
| Units: hours | | | | |
| median (full range (min-max)) | | | | |
| Cycle 1 Day 1, n=8, 18, 9, 10, 6, 15 | 7.53 (7.50 to 7.67) | 7.65 (5.73 to 8.15) | | |
| Cycle 2 Day 1, n=7, 17, 8, 8, 5, 13 | 7.55 (7.50 to 7.67) | 7.58 (7.48 to 8.25) | | |

Notes:

[55] - Only participants with available data were analyzed.

[56] - Only participants with available data were analyzed.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

up to 1385 days

Adverse event reporting additional description:

Any adverse events either reported for the first time or the worsening of pre-existing events after the first dose of study drug have been reported. Data analysis was conducted based on treatment group and dose level, regardless of study phase, because the safety profile was expected to be generally uniform across tumor types.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 25.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|--------------------------------------------------|
| Reporting group title | Phase 1 and Phase 2: INCB001158 50 mg + mFOLFOX6 |
|-----------------------|--------------------------------------------------|

Reporting group description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and MSS-CRC (Phase 2) also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|-----------------------|--------------------------------------------------|
| Reporting group title | Phase 1 and Phase 2: INCB001158 75 mg + mFOLFOX6 |
|-----------------------|--------------------------------------------------|

Reporting group description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. In Phases 1 and 2, participants with advanced or solid metastatic tumors (Phase 1) and MSS-CRC (Phase 2) also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|-----------------------|---------------------------------------------------|
| Reporting group title | Phase 1 and Phase 2: INCB001158 100 mg + mFOLFOX6 |
|-----------------------|---------------------------------------------------|

Reporting group description:

In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and MSS-CRC (Phase 2) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-fluorouracil 400 mg/m² [bolus] and 2400 mg/m² [continuous infusion]) on Day 1 and Day 15 of each 28-day cycle after administration of INCB001158.

| | |
|-----------------------|-------------------------------------------------------------|
| Reporting group title | Phase 1 and Phase 2: INCB001158 50 mg+Gemcitabine+Cisplatin |
|-----------------------|-------------------------------------------------------------|

Reporting group description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and Day 8 of each 28-day cycle. In Phase 2, participants with BTC received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 25 mg/m² on Day 1 and 8 of each 28-day cycle, and participants with OC received intravenous gemcitabine 750 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and 8 of each 28-day cycle.

| | |
|-----------------------|-------------------------------------------------------------|
| Reporting group title | Phase 1 and Phase 2: INCB001158 75 mg+Gemcitabine+Cisplatin |
|-----------------------|-------------------------------------------------------------|

Reporting group description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. Participants also received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and Day 8 of each 28-day cycle. In Phase 2, participants with BTC received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 25 mg/m² on Day 1 and 8 of each 28-day cycle, and participants with OC received intravenous gemcitabine 750 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and 8 of each 28-day cycle.

| | |
|-----------------------|--------------------------------------------------------------|
| Reporting group title | Phase 1 and Phase 2: INCB001158 100 mg+Gemcitabine+Cisplatin |
|-----------------------|--------------------------------------------------------------|

Reporting group description:

In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and with BTC or OC

(Phase 2) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. In Phase 1, participants also received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and Day 8 of each 28-day cycle. In Phase 2, participants with BTC received intravenous gemcitabine 1000 mg/m² and intravenous cisplatin 25 mg/m² on Day 1 and 8 of each 28-day cycle, and participants with OC received intravenous gemcitabine 750 mg/m² and intravenous cisplatin 30 mg/m² on Day 1 and 8 of each 28-day cycle.

| | |
|-----------------------|----------------------------------------------------|
| Reporting group title | Phase 1 and Phase 2: INCB001158 50 mg + Paclitaxel |
|-----------------------|----------------------------------------------------|

Reporting group description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 50 mg BID starting on Day 1 of each 28-day cycle. In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and with GC, EC, or OC (Phase 2) received intravenous paclitaxel 80 mg/m² on Day 1, Day 8, and Day 15 of each 28-day cycle.

| | |
|-----------------------|----------------------------------------------------|
| Reporting group title | Phase 1 and Phase 2: INCB001158 75 mg + Paclitaxel |
|-----------------------|----------------------------------------------------|

Reporting group description:

In Phase 1, participants with advanced or metastatic solid tumors received oral INCB001158 75 mg BID starting on Day 1 of each 28-day cycle. In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and with GC, EC, or OC (Phase 2) received intravenous paclitaxel 80 mg/m² on Day 1, Day 8, and Day 15 of each 28-day cycle.

| | |
|-----------------------|-----------------------------------------------------|
| Reporting group title | Phase 1 and Phase 2: INCB001158 100 mg + Paclitaxel |
|-----------------------|-----------------------------------------------------|

Reporting group description:

In Phases 1 and 2, participants with advanced or metastatic solid tumors (Phase 1) and GC, EC, or OC (Phase 2) received oral INCB001158 100 mg BID starting on Day 1 of each 28-day cycle. Participants with advanced or metastatic solid tumors (Phase 1) and with GC, EC, or OC (Phase 2) also received intravenous paclitaxel 80 mg/m² on Day 1, Day 8, and Day 15 of each 28-day cycle.

| | |
|-----------------------|-------|
| Reporting group title | Total |
|-----------------------|-------|

Reporting group description:

Total

| Serious adverse events | Phase 1 and Phase 2: INCB001158 50 mg + mFOLFOX6 | Phase 1 and Phase 2: INCB001158 75 mg + mFOLFOX6 | Phase 1 and Phase 2: INCB001158 100 mg + mFOLFOX6 |
|---------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|---------------------------------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 6 / 8 (75.00%) | 1 / 6 (16.67%) | 7 / 14 (50.00%) |
| number of deaths (all causes) | 4 | 2 | 11 |
| number of deaths resulting from adverse events | 1 | 0 | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant ascites | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |

| | | | |
|------------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| Pyrexia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Anaphylactic shock | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Female genital tract fistula | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Psychiatric disorders | | | |
| Assisted suicide | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------------------|----------------|----------------|----------------|
| Vascular access complication subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Acute myocardial infarction subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial fibrillation subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial flutter subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Supraventricular tachycardia subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Brain oedema subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| Headache | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancytopenia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|---------------|---------------|----------------|
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Duodenal obstruction | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastritis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestine perforation | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal perforation | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bile duct stone | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholangitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic haemorrhage | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Jaundice cholestatic | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Jaundice | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephritis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ureteric obstruction | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|-------------------------------------------------|---------------|---------------|----------------|
| Arthralgia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| COVID-19 pneumonia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower respiratory tract infection viral | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal candidiasis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenic sepsis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oropharyngeal candidiasis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritonitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound infection | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dehydration | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypokalaemia | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypernatraemia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Phase 1 and Phase 2: INCB001158 50 mg+Gemcitabine+Cisplatin | Phase 1 and Phase 2: INCB001158 75 mg+Gemcitabine+Cisplatin | Phase 1 and Phase 2: INCB001158 100 mg+Gemcitabine+Cisplatin |
|---------------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 3 / 7 (42.86%) | 1 / 4 (25.00%) | 30 / 46 (65.22%) |
| number of deaths (all causes) | 4 | 3 | 30 |
| number of deaths resulting from adverse events | 0 | 0 | 3 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Malignant ascites | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |

| | | | |
|------------------------------------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| General disorders and administration site conditions | | | |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|---------------|---------------|-----------------|
| Pyrexia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 5 / 46 (10.87%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Anaphylactic shock | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Female genital tract fistula | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Assisted suicide | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------------------|---------------|---------------|----------------|
| Vascular access complication subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Acute myocardial infarction subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial fibrillation subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial flutter subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Supraventricular tachycardia subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Brain oedema subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |

| | | | |
|-------------------------------------------------|----------------|---------------|-----------------|
| Headache | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancytopenia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 5 / 46 (10.87%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Duodenal obstruction | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastritis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|---------------|---------------|-----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestine perforation | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 5 / 46 (10.87%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |

| | | | |
|-------------------------------------------------|---------------|----------------|-----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal perforation | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 7 / 46 (15.22%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 7 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bile duct stone | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholangitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic haemorrhage | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |

| | | | |
|-------------------------------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Jaundice cholestatic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Jaundice | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephritis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ureteric obstruction | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| Arthralgia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Back pain | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| COVID-19 pneumonia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower respiratory tract infection viral | | | |

| | | | |
|-------------------------------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal candidiasis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenic sepsis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oropharyngeal candidiasis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritonitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |

| | | | |
|-------------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dehydration | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypokalaemia | | | |

| | | | |
|-------------------------------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypernatraemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Phase 1 and Phase 2: INCB001158 50 mg + Paclitaxel | Phase 1 and Phase 2: INCB001158 75 mg + Paclitaxel | Phase 1 and Phase 2: INCB001158 100 mg + Paclitaxel |
|---------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-----------------------------------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 4 / 7 (57.14%) | 4 / 5 (80.00%) | 27 / 52 (51.92%) |
| number of deaths (all causes) | 5 | 4 | 36 |
| number of deaths resulting from adverse events | 0 | 2 | 4 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Malignant ascites | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tumour pain | | | |

| | | | |
|------------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Device related thrombosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fatigue | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 2 / 52 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| Pyrexia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 1 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Anaphylactic shock | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Female genital tract fistula | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 4 / 52 (7.69%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |

| | | | |
|-------------------------------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Respiratory failure | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Psychiatric disorders | | | |
| Assisted suicide | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------------------|---------------|---------------|----------------|
| Vascular access complication subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Acute myocardial infarction subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial fibrillation subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial flutter subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Supraventricular tachycardia subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Brain oedema subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| Headache | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancytopenia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal distension | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 3 / 7 (42.86%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Duodenal obstruction | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastritis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ileus | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 5 (20.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestine perforation | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |

| | | | |
|-------------------------------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal perforation | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Biliary obstruction | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bile duct stone | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholangitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic haemorrhage | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperbilirubinaemia | | | |

| | | | |
|-------------------------------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Jaundice cholestatic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Jaundice | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephritis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ureteric obstruction | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|-------------------------------------------------|---------------|---------------|----------------|
| Arthralgia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Infections and infestations | | | |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| COVID-19 pneumonia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower respiratory tract infection viral | | | |

| | | | |
|-------------------------------------------------|---------------|---------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal candidiasis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neutropenic sepsis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oropharyngeal candidiasis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritonitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Septic shock | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Urinary tract infection | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dehydration | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypokalaemia | | | |

| | | | |
|-------------------------------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypernatraemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Total | | |
|---------------------------------------------------------------------|-------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 83 / 149 (55.70%) | | |
| number of deaths (all causes) | 99 | | |
| number of deaths resulting from adverse events | 11 | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Cancer pain | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Malignant ascites | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tumour pain | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|------------------------------------------------------|-----------------|--|--|
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haematoma | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| General disorders and administration site conditions | | | |
| Device related thrombosis | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Fatigue | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General physical health deterioration | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Oedema peripheral | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyrexia | | | |
| subjects affected / exposed | 9 / 149 (6.04%) | | |
| occurrences causally related to treatment / all | 1 / 11 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|-------------------------------------------------|-----------------|--|--|
| Immune system disorders | | | |
| Anaphylactic shock | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Reproductive system and breast disorders | | | |
| Female genital tract fistula | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acute respiratory failure | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Dyspnoea | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Pleural effusion | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences causally related to treatment / all | 0 / 6 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Pneumonitis | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 6 / 149 (4.03%) | | |
| occurrences causally related to treatment / all | 2 / 6 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Respiratory failure | | | |

| | | | |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Psychiatric disorders | | | |
| Assisted suicide | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Confusional state | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Mental status changes | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Investigations | | | |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood creatinine increased | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Injury, poisoning and procedural complications | | | |
| Ankle fracture | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular access complication | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|-------------------------------------------------|-----------------|--|--|
| Cardiac disorders | | | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Atrial fibrillation | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Atrial flutter | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pericardial effusion | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nervous system disorders | | | |
| Brain oedema | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Headache | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|-------------------------------------------------|-----------------|--|--|
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Syncope | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood and lymphatic system disorders | | | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences causally related to treatment / all | 1 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Leukocytosis | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pancytopenia | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Abdominal distension | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Abdominal pain | | | |
| subjects affected / exposed | 9 / 149 (6.04%) | | |
| occurrences causally related to treatment / all | 0 / 10 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | | |
|-------------------------------------------------|-----------------|--|--|--|
| Abdominal pain lower | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ascites | | | | |
| subjects affected / exposed | 7 / 149 (4.70%) | | | |
| occurrences causally related to treatment / all | 0 / 10 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Colitis | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Constipation | | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Duodenal obstruction | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diarrhoea | | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | | |
| occurrences causally related to treatment / all | 1 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastritis | | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | | |
| occurrences causally related to treatment / all | 2 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrointestinal haemorrhage | | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastrooesophageal reflux disease | | | | |

| | | | | |
|-------------------------------------------------|-----------------|--|--|--|
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ileus | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intestinal obstruction | | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | | |
| occurrences causally related to treatment / all | 0 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Large intestine perforation | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nausea | | | | |
| subjects affected / exposed | 7 / 149 (4.70%) | | | |
| occurrences causally related to treatment / all | 0 / 8 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Oesophagitis | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rectal haemorrhage | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Small intestinal obstruction | | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Small intestinal perforation | | | | |

| | | | |
|-------------------------------------------------|------------------|--|--|
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vomiting | | | |
| subjects affected / exposed | 12 / 149 (8.05%) | | |
| occurrences causally related to treatment / all | 0 / 12 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatobiliary disorders | | | |
| Biliary obstruction | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bile duct stone | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cholangitis | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatic haemorrhage | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Jaundice cholestatic | | | |

| | | | |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Jaundice | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Portal vein thrombosis | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nephritis | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urinary retention | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ureteric obstruction | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

| | | | |
|-------------------------------------------------|-----------------|--|--|
| Back pain | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Muscular weakness | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Infections and infestations | | | |
| Bacteraemia | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| COVID-19 pneumonia | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cellulitis | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infection | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences causally related to treatment / all | 0 / 6 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lower respiratory tract infection viral | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Oesophageal candidiasis | | | |

| | | | | |
|-------------------------------------------------|-----------------|--|--|--|
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Neutropenic sepsis | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Oropharyngeal candidiasis | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peritonitis | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pneumonia | | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | | |
| occurrences causally related to treatment / all | 0 / 4 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Septic shock | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Sepsis | | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | | |
| occurrences causally related to treatment / all | 0 / 4 | | | |
| deaths causally related to treatment / all | 0 / 1 | | | |
| Urinary tract infection | | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Urosepsis | | | | |

| | | | |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Viral infection | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Wound infection | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Dehydration | | | |
| subjects affected / exposed | 6 / 149 (4.03%) | | |
| occurrences causally related to treatment / all | 0 / 7 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypokalaemia | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypernatraemia | | | |

| | | | |
|-------------------------------------------------|-----------------|--|--|
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hyponatraemia | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Phase 1 and Phase 2: INCB001158 50 mg + mFOLFOX6 | Phase 1 and Phase 2: INCB001158 75 mg + mFOLFOX6 | Phase 1 and Phase 2: INCB001158 100 mg + mFOLFOX6 |
|---------------------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|---------------------------------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 8 / 8 (100.00%) | 6 / 6 (100.00%) | 13 / 14 (92.86%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tumour haemorrhage | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tumour pain | | | |
| subjects affected / exposed | 3 / 8 (37.50%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 4 | 1 | 2 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Embolism | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |

| | | | |
|------------------------------------------------------|----------------|----------------|-----------------|
| Haematoma | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Hot flush | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 1 | 0 | 2 |
| Hypotension | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 0 | 0 | 3 |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 2 |
| Catheter site erythema | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Chills | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Fatigue | | | |
| subjects affected / exposed | 3 / 8 (37.50%) | 4 / 6 (66.67%) | 4 / 14 (28.57%) |
| occurrences (all) | 5 | 4 | 5 |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Infusion site extravasation | | | |

| | | | |
|-----------------------------|----------------|---------------|-----------------|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mucosal ulceration | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 2 | 0 | 2 |
| Oedema | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pyrexia | | | |
| subjects affected / exposed | 3 / 8 (37.50%) | 0 / 6 (0.00%) | 3 / 14 (21.43%) |
| occurrences (all) | 3 | 0 | 3 |
| Swelling | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Immune system disorders | | | |

| | | | |
|-----------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 1 / 6 (16.67%) 1 | 1 / 14 (7.14%) 1 |
| Reproductive system and breast disorders | | | |
| Intermenstrual bleeding subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Pelvic pain subjects affected / exposed occurrences (all) | 1 / 8 (12.50%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough subjects affected / exposed occurrences (all) | 3 / 8 (37.50%) 3 | 1 / 6 (16.67%) 2 | 3 / 14 (21.43%) 3 |
| Dyspnoea subjects affected / exposed occurrences (all) | 1 / 8 (12.50%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Dysphonia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Dyspnoea exertional subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Epistaxis subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 1 / 6 (16.67%) 2 | 0 / 14 (0.00%) 0 |
| Hiccups subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Hypoxia subjects affected / exposed occurrences (all) | 1 / 8 (12.50%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Oropharyngeal pain subjects affected / exposed occurrences (all) | 1 / 8 (12.50%) 1 | 1 / 6 (16.67%) 2 | 0 / 14 (0.00%) 0 |
| Pneumonitis | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 0 | 1 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Delirium | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Insomnia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Alanine aminotransferase increased | | | |

| | | | |
|---------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 2 |
| Ammonia increased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Amylase increased | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 6 (16.67%) | 4 / 14 (28.57%) |
| occurrences (all) | 1 | 1 | 4 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Blood magnesium decreased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 2 | 1 | 1 |
| Blood potassium decreased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Lipase increased | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 6 (16.67%) | 2 / 14 (14.29%) |
| occurrences (all) | 1 | 3 | 2 |
| Neutrophil count decreased | | | |

| | | | |
|------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 4 / 8 (50.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 5 | 1 | 0 |
| Platelet count decreased | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 3 / 6 (50.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 1 | 4 | 4 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 3 / 14 (21.43%) |
| occurrences (all) | 0 | 1 | 3 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 4 | 1 | 0 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fall | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 2 |
| Infusion related reaction | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 3 | 1 |
| Procedural haemorrhage | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin laceration | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 2 |
| Stoma site erythema | | | |

| | | | |
|------------------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Wound dehiscence subjects affected / exposed occurrences (all) | 1 / 8 (12.50%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Cardiac disorders | | | |
| Bradycardia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Cardiac disorder subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Palpitations subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Supraventricular extrasystoles subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Tachycardia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Nervous system disorders | | | |
| Autonomic neuropathy subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Balance disorder subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Dizziness subjects affected / exposed occurrences (all) | 1 / 8 (12.50%) 2 | 1 / 6 (16.67%) 1 | 2 / 14 (14.29%) 2 |
| Dysaesthesia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Dysgeusia | | | |

| | | | |
|--------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Headache | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 2 / 14 (14.29%) |
| occurrences (all) | 0 | 1 | 2 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 2 / 14 (14.29%) |
| occurrences (all) | 0 | 1 | 2 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 3 / 6 (50.00%) | 4 / 14 (28.57%) |
| occurrences (all) | 0 | 4 | 4 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Syncope | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 2 |
| Taste disorder | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tremor | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 4 / 8 (50.00%) | 2 / 6 (33.33%) | 2 / 14 (14.29%) |
| occurrences (all) | 4 | 2 | 2 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|--------------------------------|----------------|----------------|-----------------|
| Leukopenia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Neutropenia | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 1 / 6 (16.67%) | 5 / 14 (35.71%) |
| occurrences (all) | 2 | 1 | 5 |
| Normocytic anaemia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 1 | 1 |
| Ear and labyrinth disorders | | | |
| Deafness | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Tinnitus | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Eye disorders | | | |
| Foreign body sensation in eyes | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Glaucoma | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Retinopathy | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitreous floaters | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastrointestinal disorders | | | |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 1 / 6 (16.67%) | 5 / 14 (35.71%) |
| occurrences (all) | 2 | 1 | 7 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 2 / 14 (14.29%) |
| occurrences (all) | 0 | 1 | 2 |
| Ascites | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Cheilitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 1 / 6 (16.67%) | 2 / 14 (14.29%) |
| occurrences (all) | 2 | 3 | 2 |
| Diarrhoea | | | |
| subjects affected / exposed | 3 / 8 (37.50%) | 3 / 6 (50.00%) | 6 / 14 (42.86%) |
| occurrences (all) | 6 | 4 | 7 |
| Dry mouth | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dysphagia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|------------------------------------|----------------|----------------|-----------------|
| Faeces soft | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Glossodynia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Lower gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 5 / 8 (62.50%) | 3 / 6 (50.00%) | 5 / 14 (35.71%) |
| occurrences (all) | 7 | 6 | 5 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Proctalgia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retching | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 2 / 6 (33.33%) | 3 / 14 (21.43%) |
| occurrences (all) | 0 | 2 | 3 |

| | | | |
|-------------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| Vomiting subjects affected / exposed occurrences (all) | 3 / 8 (37.50%) 3 | 1 / 6 (16.67%) 1 | 3 / 14 (21.43%) 3 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Dermatitis acneiform subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Drug eruption subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Dry skin subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Hyperhidrosis subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Nail disorder subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Photosensitivity reaction subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Pruritus subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Rash maculo-papular subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 1 / 6 (16.67%) 2 | 0 / 14 (0.00%) 0 |
| Rash subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Renal and urinary disorders | | | |

| | | | |
|-------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| Acute kidney injury subjects affected / exposed occurrences (all) | 1 / 8 (12.50%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Dysuria subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Haematuria subjects affected / exposed occurrences (all) | 1 / 8 (12.50%) 1 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Proteinuria subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Renal failure subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Hypothyroidism subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 2 / 14 (14.29%) 2 |
| Back pain subjects affected / exposed occurrences (all) | 3 / 8 (37.50%) 4 | 2 / 6 (33.33%) 2 | 1 / 14 (7.14%) 2 |
| Groin pain subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Limb discomfort subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Myalgia | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 2 / 8 (25.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 2 | 1 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Osteonecrosis of jaw | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sacral pain | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Infections and infestations | | | |
| Biliary tract infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Enterocolitis infectious | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |

| | | | |
|-----------------------------------|----------------|----------------|-----------------|
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infection | | | |
| subjects affected / exposed | 2 / 8 (25.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Lip infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 0 | 0 | 2 |
| Peritonitis | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 1 | 1 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 1 / 6 (16.67%) | 2 / 14 (14.29%) |
| occurrences (all) | 0 | 1 | 3 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---------------------------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| Viral upper respiratory tract infection subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite subjects affected / exposed occurrences (all) | 3 / 8 (37.50%) 3 | 2 / 6 (33.33%) 2 | 4 / 14 (28.57%) 4 |
| Dehydration subjects affected / exposed occurrences (all) | 1 / 8 (12.50%) 2 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 2 |
| Food intolerance subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Hypercholesterolaemia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Hypercalcaemia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Hyperglycaemia subjects affected / exposed occurrences (all) | 2 / 8 (25.00%) 7 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Hypernatraemia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Hyperkalaemia subjects affected / exposed occurrences (all) | 0 / 8 (0.00%) 0 | 1 / 6 (16.67%) 1 | 0 / 14 (0.00%) 0 |
| Hypertriglyceridaemia subjects affected / exposed occurrences (all) | 2 / 8 (25.00%) 3 | 0 / 6 (0.00%) 0 | 0 / 14 (0.00%) 0 |
| Hyperuricaemia subjects affected / exposed occurrences (all) | 1 / 8 (12.50%) 1 | 0 / 6 (0.00%) 0 | 1 / 14 (7.14%) 1 |
| Hypoalbuminaemia | | | |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 6 (16.67%) | 1 / 14 (7.14%) |
| occurrences (all) | 2 | 2 | 1 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 2 | 0 | 1 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 1 | 0 | 1 |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 2 / 14 (14.29%) |
| occurrences (all) | 2 | 0 | 3 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 8 (12.50%) | 1 / 6 (16.67%) | 2 / 14 (14.29%) |
| occurrences (all) | 1 | 1 | 3 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 0 / 14 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 8 (0.00%) | 0 / 6 (0.00%) | 1 / 14 (7.14%) |
| occurrences (all) | 0 | 0 | 1 |

| Non-serious adverse events | Phase 1 and Phase 2: INCB001158 50 mg+Gemcitabine+Ci splat | Phase 1 and Phase 2: INCB001158 75 mg+Gemcitabine+Ci splat | Phase 1 and Phase 2: INCB001158 100 mg+Gemcitabine+Ci splat |
|---------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 7 / 7 (100.00%) | 4 / 4 (100.00%) | 45 / 46 (97.83%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tumour haemorrhage | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Tumour pain | | | |

| | | | |
|---------------------------------------------------------|--------------------|--------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 4 / 46 (8.70%) |
| occurrences (all) | 0 | 0 | 4 |
| Embolism | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Haematoma | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hot flush | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypertension | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypotension | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lymphoedema | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Catheter site erythema | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 4 / 46 (8.70%) |
| occurrences (all) | 0 | 0 | 5 |
| Fatigue | | | |

| | | | |
|---------------------------------------|----------------|----------------|------------------|
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 4 (25.00%) | 23 / 46 (50.00%) |
| occurrences (all) | 1 | 1 | 33 |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 1 | 0 | 2 |
| Infusion site extravasation | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Mucosal ulceration | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 2 / 7 (28.57%) | 0 / 4 (0.00%) | 9 / 46 (19.57%) |
| occurrences (all) | 2 | 0 | 10 |
| Oedema | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 0 | 3 |
| Pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 0 | 2 |
| Peripheral swelling | | | |

| | | | |
|-------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|-----------------------|
| subjects affected / exposed occurrences (all) | 1 / 7 (14.29%) 1 | 0 / 4 (0.00%) 0 | 4 / 46 (8.70%) 5 |
| Pyrexia subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 9 / 46 (19.57%) 11 |
| Swelling subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 1 / 46 (2.17%) 1 |
| Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Reproductive system and breast disorders Intermenstrual bleeding subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Pelvic pain subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 1 / 46 (2.17%) 1 |
| Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 1 / 4 (25.00%) 1 | 9 / 46 (19.57%) 9 |
| Dyspnoea subjects affected / exposed occurrences (all) | 2 / 7 (28.57%) 2 | 1 / 4 (25.00%) 1 | 8 / 46 (17.39%) 9 |
| Dysphonia subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Dyspnoea exertional subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 1 / 4 (25.00%) 1 | 2 / 46 (4.35%) 3 |
| Epistaxis subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 2 / 46 (4.35%) 3 |
| Hiccups | | | |

| | | | |
|-----------------------------|---------------|----------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 0 | 3 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 0 | 3 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Delirium | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-------------------------------------------------|----------------|----------------|------------------|
| Insomnia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 8 / 46 (17.39%) |
| occurrences (all) | 0 | 0 | 8 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 4 (25.00%) | 9 / 46 (19.57%) |
| occurrences (all) | 1 | 1 | 18 |
| Ammonia increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 2 | 1 |
| Amylase increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 3 / 7 (42.86%) | 0 / 4 (0.00%) | 9 / 46 (19.57%) |
| occurrences (all) | 3 | 0 | 14 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 1 | 0 | 4 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood magnesium decreased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Blood creatinine increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 13 / 46 (28.26%) |
| occurrences (all) | 0 | 1 | 18 |
| Blood potassium decreased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone increased | | | |

| | | | |
|------------------------------------------------|----------------|----------------|------------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lipase increased | | | |
| subjects affected / exposed | 3 / 7 (42.86%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 5 | 0 | 5 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 4 / 7 (57.14%) | 0 / 4 (0.00%) | 15 / 46 (32.61%) |
| occurrences (all) | 5 | 0 | 31 |
| Platelet count decreased | | | |
| subjects affected / exposed | 5 / 7 (71.43%) | 0 / 4 (0.00%) | 14 / 46 (30.43%) |
| occurrences (all) | 9 | 0 | 29 |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 0 | 2 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 5 / 7 (71.43%) | 1 / 4 (25.00%) | 8 / 46 (17.39%) |
| occurrences (all) | 6 | 1 | 13 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 0 | 3 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Fall | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infusion related reaction | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Procedural haemorrhage | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |

| | | | |
|------------------------------------------------------------------------------------|--------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Skin laceration subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Stoma site erythema subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Wound dehiscence subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Cardiac disorders | | | |
| Bradycardia subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Cardiac disorder subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Palpitations subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 1 / 4 (25.00%) 1 | 1 / 46 (2.17%) 1 |
| Supraventricular extrasystoles subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Tachycardia subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 1 / 46 (2.17%) 1 |
| Nervous system disorders | | | |
| Autonomic neuropathy subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Balance disorder subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Dizziness | | | |

| | | | |
|---------------------------------------------|----------------|----------------|------------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 11 / 46 (23.91%) |
| occurrences (all) | 0 | 0 | 13 |
| Dysaesthesia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 1 | 3 |
| Headache | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 10 / 46 (21.74%) |
| occurrences (all) | 0 | 0 | 14 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 1 | 2 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 6 / 46 (13.04%) |
| occurrences (all) | 0 | 0 | 7 |
| Paraesthesia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 1 | 0 | 2 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 6 / 46 (13.04%) |
| occurrences (all) | 0 | 1 | 7 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Syncope | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Taste disorder | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tremor | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |

| | | | |
|--------------------------------|----------------|----------------|------------------|
| Anaemia | | | |
| subjects affected / exposed | 5 / 7 (71.43%) | 2 / 4 (50.00%) | 25 / 46 (54.35%) |
| occurrences (all) | 5 | 2 | 38 |
| Leukocytosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 0 | 2 |
| Leukopenia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neutropenia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 4 (25.00%) | 11 / 46 (23.91%) |
| occurrences (all) | 1 | 1 | 25 |
| Normocytic anaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 4 (25.00%) | 10 / 46 (21.74%) |
| occurrences (all) | 1 | 2 | 16 |
| Ear and labyrinth disorders | | | |
| Deafness | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tinnitus | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 5 / 46 (10.87%) |
| occurrences (all) | 1 | 0 | 5 |
| Eye disorders | | | |
| Foreign body sensation in eyes | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Glaucoma | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinopathy | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Vision blurred | | | |

| | | | |
|-----------------------------|----------------|----------------|------------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 0 | 3 |
| Vitreous floaters | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 2 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 0 | 2 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 5 / 46 (10.87%) |
| occurrences (all) | 0 | 0 | 5 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 4 (25.00%) | 9 / 46 (19.57%) |
| occurrences (all) | 1 | 1 | 18 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 0 | 2 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 4 / 46 (8.70%) |
| occurrences (all) | 0 | 0 | 4 |
| Ascites | | | |
| subjects affected / exposed | 3 / 7 (42.86%) | 0 / 4 (0.00%) | 4 / 46 (8.70%) |
| occurrences (all) | 3 | 0 | 5 |
| Cheilitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Constipation | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 2 / 4 (50.00%) | 19 / 46 (41.30%) |
| occurrences (all) | 0 | 2 | 29 |
| Diarrhoea | | | |
| subjects affected / exposed | 2 / 7 (28.57%) | 0 / 4 (0.00%) | 11 / 46 (23.91%) |
| occurrences (all) | 4 | 0 | 17 |
| Dry mouth | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|------------------------------------|----------------|----------------|------------------|
| Dyspepsia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 5 / 46 (10.87%) |
| occurrences (all) | 0 | 0 | 6 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Faeces soft | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 1 | 3 |
| Glossodynia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 0 | 3 |
| Lower gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 4 (25.00%) | 25 / 46 (54.35%) |
| occurrences (all) | 1 | 1 | 44 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Proctalgia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|----------------------------------------|----------------|----------------|------------------|
| Retching | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 6 / 46 (13.04%) |
| occurrences (all) | 0 | 0 | 6 |
| Vomiting | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 4 (25.00%) | 14 / 46 (30.43%) |
| occurrences (all) | 1 | 1 | 26 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 1 | 2 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Drug eruption | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nail disorder | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 0 | 5 |
| Rash maculo-papular | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 2 / 4 (50.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 2 | 2 |
| Rash | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 5 / 46 (10.87%) |
| occurrences (all) | 0 | 0 | 5 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 0 | 2 |
| Dysuria | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 0 | 2 |
| Haematuria | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 1 | 0 | 1 |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal failure | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Endocrine disorders | | | |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Hypothyroidism | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 2 / 7 (28.57%) | 0 / 4 (0.00%) | 8 / 46 (17.39%) |
| occurrences (all) | 2 | 0 | 10 |
| Back pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 9 / 46 (19.57%) |
| occurrences (all) | 0 | 0 | 14 |
| Groin pain | | | |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Limb discomfort | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Myalgia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 1 | 0 | 1 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 0 | 3 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 7 / 46 (15.22%) |
| occurrences (all) | 0 | 0 | 9 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Osteonecrosis of jaw | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 0 | 3 |
| Sacral pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Biliary tract infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 0 | 3 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|-----------------------------------|----------------|---------------|----------------|
| Ear infection | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Enterocolitis infectious | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 0 | 3 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oral candidiasis | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Peritonitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin infection | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 1 | 0 | 1 |

| | | | |
|---------------------------------------------------------------------------------------------|---------------------|---------------------|------------------------|
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 1 / 7 (14.29%) 1 | 0 / 4 (0.00%) 0 | 5 / 46 (10.87%) 5 |
| Urinary tract infection subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 6 / 46 (13.04%) 7 |
| Viral upper respiratory tract infection subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 1 / 46 (2.17%) 1 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite subjects affected / exposed occurrences (all) | 2 / 7 (28.57%) 2 | 1 / 4 (25.00%) 1 | 12 / 46 (26.09%) 14 |
| Dehydration subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 3 / 46 (6.52%) 4 |
| Food intolerance subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Hypercholesterolaemia subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Hypercalcaemia subjects affected / exposed occurrences (all) | 1 / 7 (14.29%) 1 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Hyperglycaemia subjects affected / exposed occurrences (all) | 3 / 7 (42.86%) 4 | 0 / 4 (0.00%) 0 | 2 / 46 (4.35%) 3 |
| Hypernatraemia subjects affected / exposed occurrences (all) | 1 / 7 (14.29%) 1 | 0 / 4 (0.00%) 0 | 0 / 46 (0.00%) 0 |
| Hyperkalaemia subjects affected / exposed occurrences (all) | 1 / 7 (14.29%) 1 | 0 / 4 (0.00%) 0 | 3 / 46 (6.52%) 3 |
| Hypertriglyceridaemia | | | |

| | | | |
|-----------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 1 / 46 (2.17%) |
| occurrences (all) | 2 | 0 | 1 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 0 | 3 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 5 / 46 (10.87%) |
| occurrences (all) | 3 | 0 | 5 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 7 / 46 (15.22%) |
| occurrences (all) | 0 | 0 | 7 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 3 / 46 (6.52%) |
| occurrences (all) | 0 | 0 | 3 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 6 / 46 (13.04%) |
| occurrences (all) | 0 | 0 | 6 |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 4 (25.00%) | 5 / 46 (10.87%) |
| occurrences (all) | 0 | 1 | 8 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 2 / 46 (4.35%) |
| occurrences (all) | 0 | 0 | 2 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 4 (0.00%) | 0 / 46 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| Non-serious adverse events | Phase 1 and Phase 2: INCB001158 50 mg + Paclitaxel | Phase 1 and Phase 2: INCB001158 75 mg + Paclitaxel | Phase 1 and Phase 2: INCB001158 100 mg + Paclitaxel |
|---------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-----------------------------------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 7 / 7 (100.00%) | 5 / 5 (100.00%) | 50 / 52 (96.15%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|---------------------------------------------------------------------------|---------------------|--------------------|-----------------------|
| Seborrhoeic keratosis subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 0 / 52 (0.00%) 0 |
| Tumour haemorrhage subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 0 / 52 (0.00%) 0 |
| Tumour pain subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 1 / 52 (1.92%) 1 |
| Vascular disorders | | | |
| Deep vein thrombosis subjects affected / exposed occurrences (all) | 1 / 7 (14.29%) 1 | 0 / 5 (0.00%) 0 | 3 / 52 (5.77%) 3 |
| Embolism subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 0 / 52 (0.00%) 0 |
| Haematoma subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 1 / 52 (1.92%) 1 |
| Hot flush subjects affected / exposed occurrences (all) | 1 / 7 (14.29%) 1 | 0 / 5 (0.00%) 0 | 8 / 52 (15.38%) 12 |
| Hypertension subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 4 / 52 (7.69%) 4 |
| Hypotension subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 2 / 52 (3.85%) 2 |
| Lymphoedema subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 3 / 52 (5.77%) 3 |
| General disorders and administration site conditions | | | |
| Asthenia subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 1 / 52 (1.92%) 1 |
| Catheter site erythema | | | |

| | | | |
|---------------------------------------|----------------|----------------|------------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Chills | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 5 |
| Fatigue | | | |
| subjects affected / exposed | 2 / 7 (28.57%) | 4 / 5 (80.00%) | 29 / 52 (55.77%) |
| occurrences (all) | 2 | 5 | 38 |
| General physical health deterioration | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 0 | 5 |
| Infusion site extravasation | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Localised oedema | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Malaise | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 4 |
| Mucosal inflammation | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 0 | 4 |
| Mucosal ulceration | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 5 (20.00%) | 13 / 52 (25.00%) |
| occurrences (all) | 1 | 1 | 20 |
| Oedema | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Non-cardiac chest pain | | | |

| | | | |
|-------------------------------------------------|----------------|----------------|-----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 2 / 5 (40.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 2 / 5 (40.00%) | 6 / 52 (11.54%) |
| occurrences (all) | 0 | 2 | 8 |
| Swelling | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Immune system disorders | | | |
| Hypersensitivity | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Intermenstrual bleeding | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pelvic pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 2 / 5 (40.00%) | 8 / 52 (15.38%) |
| occurrences (all) | 0 | 2 | 10 |
| Dyspnoea | | | |
| subjects affected / exposed | 4 / 7 (57.14%) | 0 / 5 (0.00%) | 7 / 52 (13.46%) |
| occurrences (all) | 4 | 0 | 12 |
| Dysphonia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 4 |
| Dyspnoea exertional | | | |

| | | | |
|-----------------------------|----------------|---------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 0 | 5 |
| Hiccups | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypoxia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 1 | 0 | 5 |
| Pneumonitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 0 | 0 | 2 |
| Rhinitis allergic | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 4 |
| Rhinorrhoea | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 0 | 0 | 2 |
| Wheezing | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 2 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 0 | 0 | 6 |

| | | | |
|-------------------------------------------------|---------------|----------------|-----------------|
| Confusional state | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Delirium | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 0 | 1 | 5 |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 0 | 0 | 2 |
| Ammonia increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Amylase increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 8 |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 4 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 6 / 52 (11.54%) |
| occurrences (all) | 0 | 0 | 6 |
| Blood cholesterol increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood magnesium decreased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood creatinine increased | | | |

| | | | |
|------------------------------------------------|----------------|----------------|------------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 8 / 52 (15.38%) |
| occurrences (all) | 0 | 0 | 9 |
| Blood potassium decreased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 7 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 6 |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 9 / 52 (17.31%) |
| occurrences (all) | 0 | 1 | 19 |
| Platelet count decreased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 1 | 6 |
| Weight decreased | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 1 | 0 | 5 |
| White blood cell count decreased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 11 / 52 (21.15%) |
| occurrences (all) | 0 | 0 | 28 |
| Weight increased | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 0 | 4 |
| Fall | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 0 | 0 | 2 |
| Infusion related reaction | | | |

| | | | |
|--------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Procedural haemorrhage | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin laceration | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Stoma site erythema | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Wound dehiscence | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Cardiac disorder | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Palpitations | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Supraventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Nervous system disorders | | | |
| Autonomic neuropathy | | | |

| | | | |
|-------------------------------|----------------|----------------|------------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Balance disorder | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dizziness | | | |
| subjects affected / exposed | 2 / 7 (28.57%) | 0 / 5 (0.00%) | 10 / 52 (19.23%) |
| occurrences (all) | 2 | 0 | 13 |
| Dysaesthesia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dysgeusia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 6 / 52 (11.54%) |
| occurrences (all) | 0 | 0 | 12 |
| Headache | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 9 / 52 (17.31%) |
| occurrences (all) | 0 | 0 | 9 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 3 / 7 (42.86%) | 0 / 5 (0.00%) | 10 / 52 (19.23%) |
| occurrences (all) | 3 | 0 | 12 |
| Paraesthesia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 0 | 0 | 5 |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 2 / 5 (40.00%) | 10 / 52 (19.23%) |
| occurrences (all) | 1 | 2 | 11 |
| Somnolence | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Syncope | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 1 | 0 | 4 |
| Taste disorder | | | |

| | | | |
|------------------------------------------------------------------------------------|---------------------|---------------------|------------------------|
| subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 2 / 52 (3.85%) 2 |
| Tremor subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 1 / 52 (1.92%) 1 |
| Blood and lymphatic system disorders | | | |
| Anaemia subjects affected / exposed occurrences (all) | 2 / 7 (28.57%) 3 | 1 / 5 (20.00%) 2 | 21 / 52 (40.38%) 30 |
| Leukocytosis subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 3 / 52 (5.77%) 4 |
| Leukopenia subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 2 / 52 (3.85%) 4 |
| Neutropenia subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 7 / 52 (13.46%) 17 |
| Normocytic anaemia subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 0 / 52 (0.00%) 0 |
| Thrombocytopenia subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 1 / 52 (1.92%) 1 |
| Ear and labyrinth disorders | | | |
| Deafness subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 0 / 52 (0.00%) 0 |
| Tinnitus subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 2 / 52 (3.85%) 2 |
| Eye disorders | | | |
| Foreign body sensation in eyes subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 0 / 52 (0.00%) 0 |
| Glaucoma | | | |

| | | | |
|-----------------------------|----------------|----------------|------------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Retinopathy | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vision blurred | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Vitreous floaters | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 0 | 0 | 2 |
| Abdominal distension | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 8 / 52 (15.38%) |
| occurrences (all) | 1 | 0 | 11 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 15 / 52 (28.85%) |
| occurrences (all) | 1 | 0 | 19 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 0 | 0 | 8 |
| Ascites | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 2 | 0 | 7 |
| Cheilitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 0 | 4 |
| Constipation | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 1 / 5 (20.00%) | 13 / 52 (25.00%) |
| occurrences (all) | 1 | 1 | 13 |

| | | | |
|------------------------------------|----------------|----------------|------------------|
| Diarrhoea | | | |
| subjects affected / exposed | 3 / 7 (42.86%) | 1 / 5 (20.00%) | 16 / 52 (30.77%) |
| occurrences (all) | 3 | 1 | 25 |
| Dry mouth | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 1 | 0 | 1 |
| Dyspepsia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 1 | 0 | 2 |
| Dysphagia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Faeces soft | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 0 | 4 |
| Glossodynia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lower gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 3 / 7 (42.86%) | 3 / 5 (60.00%) | 21 / 52 (40.38%) |
| occurrences (all) | 4 | 3 | 43 |
| Oesophagitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|----------------------------------------|----------------|----------------|------------------|
| Proctalgia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 1 | 0 | 1 |
| Retching | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Stomatitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 10 / 52 (19.23%) |
| occurrences (all) | 0 | 0 | 12 |
| Vomiting | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 3 / 5 (60.00%) | 18 / 52 (34.62%) |
| occurrences (all) | 2 | 6 | 29 |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 2 / 5 (40.00%) | 18 / 52 (34.62%) |
| occurrences (all) | 1 | 2 | 20 |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Drug eruption | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Hyperhidrosis | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 1 | 0 | 5 |
| Nail disorder | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 0 | 0 | 6 |
| Photosensitivity reaction | | | |

| | | | |
|--------------------------------------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 0 / 52 (0.00%) 0 |
| Pruritus subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 1 / 5 (20.00%) 1 | 6 / 52 (11.54%) 8 |
| Rash maculo-papular subjects affected / exposed occurrences (all) | 1 / 7 (14.29%) 1 | 0 / 5 (0.00%) 0 | 6 / 52 (11.54%) 9 |
| Rash subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 1 / 5 (20.00%) 1 | 7 / 52 (13.46%) 7 |
| Renal and urinary disorders Acute kidney injury subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 1 / 52 (1.92%) 2 |
| Dysuria subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 3 / 52 (5.77%) 4 |
| Haematuria subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 2 / 52 (3.85%) 3 |
| Proteinuria subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 0 / 52 (0.00%) 0 |
| Renal failure subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 0 / 52 (0.00%) 0 |
| Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 1 / 52 (1.92%) 1 |
| Hypothyroidism subjects affected / exposed occurrences (all) | 0 / 7 (0.00%) 0 | 0 / 5 (0.00%) 0 | 6 / 52 (11.54%) 7 |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|-----------------------------|----------------|----------------|------------------|
| Arthralgia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 11 / 52 (21.15%) |
| occurrences (all) | 0 | 1 | 13 |
| Back pain | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 9 / 52 (17.31%) |
| occurrences (all) | 1 | 0 | 10 |
| Groin pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Limb discomfort | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Myalgia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 7 / 52 (13.46%) |
| occurrences (all) | 0 | 0 | 9 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 6 |
| Muscle spasms | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 1 | 0 | 6 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 2 | 1 |
| Osteonecrosis of jaw | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 2 / 5 (40.00%) | 4 / 52 (7.69%) |
| occurrences (all) | 0 | 2 | 4 |
| Sacral pain | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Biliary tract infection | | | |

| | | | |
|-----------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Enterocolitis infectious | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lip infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 1 | 0 | 1 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 0 | 0 | 3 |
| Oral candidiasis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peritonitis | | | |

| | | | |
|-----------------------------------------|----------------|----------------|------------------|
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 1 / 5 (20.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 1 | 1 |
| Skin infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 0 | 0 | 2 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 7 / 52 (13.46%) |
| occurrences (all) | 1 | 0 | 9 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 6 / 52 (11.54%) |
| occurrences (all) | 1 | 0 | 15 |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 2 / 7 (28.57%) | 1 / 5 (20.00%) | 10 / 52 (19.23%) |
| occurrences (all) | 2 | 1 | 16 |
| Dehydration | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 9 / 52 (17.31%) |
| occurrences (all) | 0 | 0 | 10 |
| Food intolerance | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypercholesterolaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypercalcaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 0 | 0 | 8 |

| | | | |
|-----------------------------|----------------|---------------|-----------------|
| Hypernatraemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 1 | 0 | 5 |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 0 | 0 | 3 |
| Hyperuricaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 2 / 7 (28.57%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 2 | 0 | 3 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 2 / 7 (28.57%) | 0 / 5 (0.00%) | 2 / 52 (3.85%) |
| occurrences (all) | 3 | 0 | 2 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 0 / 52 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 8 / 52 (15.38%) |
| occurrences (all) | 2 | 0 | 12 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 3 / 52 (5.77%) |
| occurrences (all) | 1 | 0 | 3 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 7 (14.29%) | 0 / 5 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 2 | 0 | 9 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 5 / 52 (9.62%) |
| occurrences (all) | 0 | 0 | 5 |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 0 / 7 (0.00%) | 0 / 5 (0.00%) | 1 / 52 (1.92%) |
| occurrences (all) | 0 | 0 | 1 |

| Non-serious adverse events | Total | | |
|---------------------------------------------------------------------|--------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 145 / 149 (97.32%) | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Seborrhoeic keratosis | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Tumour haemorrhage | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Tumour pain | | | |
| subjects affected / exposed | 6 / 149 (4.03%) | | |
| occurrences (all) | 8 | | |
| Vascular disorders | | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 10 / 149 (6.71%) | | |
| occurrences (all) | 10 | | |
| Embolism | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| Haematoma | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Hot flush | | | |
| subjects affected / exposed | 9 / 149 (6.04%) | | |
| occurrences (all) | 13 | | |
| Hypertension | | | |
| subjects affected / exposed | 8 / 149 (5.37%) | | |
| occurrences (all) | 8 | | |
| Hypotension | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 6 | | |
| Lymphoedema | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| General disorders and administration | | | |

| | | | |
|---------------------------------------|-------------------|--|--|
| site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 4 | | |
| Catheter site erythema | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Chills | | | |
| subjects affected / exposed | 8 / 149 (5.37%) | | |
| occurrences (all) | 11 | | |
| Fatigue | | | |
| subjects affected / exposed | 71 / 149 (47.65%) | | |
| occurrences (all) | 94 | | |
| General physical health deterioration | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Influenza like illness | | | |
| subjects affected / exposed | 8 / 149 (5.37%) | | |
| occurrences (all) | 9 | | |
| Infusion site extravasation | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Localised oedema | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Malaise | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 5 | | |
| Mucosal inflammation | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 5 | | |
| Mucosal ulceration | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Oedema peripheral | | | |

| | | | |
|-------------------------------------------------|-------------------|--|--|
| subjects affected / exposed | 29 / 149 (19.46%) | | |
| occurrences (all) | 38 | | |
| Oedema | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 5 | | |
| Pain | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 4 | | |
| Peripheral swelling | | | |
| subjects affected / exposed | 6 / 149 (4.03%) | | |
| occurrences (all) | 7 | | |
| Pyrexia | | | |
| subjects affected / exposed | 23 / 149 (15.44%) | | |
| occurrences (all) | 27 | | |
| Swelling | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| Immune system disorders | | | |
| Hypersensitivity | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| Reproductive system and breast disorders | | | |
| Intermenstrual bleeding | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Pelvic pain | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 27 / 149 (18.12%) | | |
| occurrences (all) | 30 | | |
| Dyspnoea | | | |

| | | | |
|-----------------------------|-------------------|--|--|
| subjects affected / exposed | 23 / 149 (15.44%) | | |
| occurrences (all) | 29 | | |
| Dysphonia | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 5 | | |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 4 | | |
| Epistaxis | | | |
| subjects affected / exposed | 7 / 149 (4.70%) | | |
| occurrences (all) | 10 | | |
| Hiccups | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 5 | | |
| Hypoxia | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 9 / 149 (6.04%) | | |
| occurrences (all) | 10 | | |
| Pneumonitis | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| Pleural effusion | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 7 / 149 (4.70%) | | |
| occurrences (all) | 7 | | |
| Rhinitis allergic | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 4 | | |
| Rhinorrhoea | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| Wheezing | | | |

| | | | |
|-------------------------------------------------|-------------------|--|--|
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 3 | | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 7 / 149 (4.70%) | | |
| occurrences (all) | 8 | | |
| Confusional state | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Delirium | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Insomnia | | | |
| subjects affected / exposed | 15 / 149 (10.07%) | | |
| occurrences (all) | 16 | | |
| Investigations | | | |
| Activated partial thromboplastin time prolonged | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 14 / 149 (9.40%) | | |
| occurrences (all) | 24 | | |
| Ammonia increased | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 3 | | |
| Amylase increased | | | |
| subjects affected / exposed | 7 / 149 (4.70%) | | |
| occurrences (all) | 13 | | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 16 / 149 (10.74%) | | |
| occurrences (all) | 22 | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 16 / 149 (10.74%) | | |
| occurrences (all) | 17 | | |
| Blood cholesterol increased | | | |

| | | | |
|------------------------------------------------|-------------------|--|--|
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Blood magnesium decreased | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Blood creatinine increased | | | |
| subjects affected / exposed | 26 / 149 (17.45%) | | |
| occurrences (all) | 32 | | |
| Blood potassium decreased | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Blood thyroid stimulating hormone increased | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 8 | | |
| Lipase increased | | | |
| subjects affected / exposed | 12 / 149 (8.05%) | | |
| occurrences (all) | 22 | | |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 34 / 149 (22.82%) | | |
| occurrences (all) | 62 | | |
| Platelet count decreased | | | |
| subjects affected / exposed | 29 / 149 (19.46%) | | |
| occurrences (all) | 54 | | |
| Weight decreased | | | |
| subjects affected / exposed | 12 / 149 (8.05%) | | |
| occurrences (all) | 12 | | |
| White blood cell count decreased | | | |
| subjects affected / exposed | 28 / 149 (18.79%) | | |
| occurrences (all) | 53 | | |
| Weight increased | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 4 | | |
| Injury, poisoning and procedural complications | | | |

| | | | |
|--------------------------------|-----------------|--|--|
| Contusion | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 5 | | |
| Fall | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 4 | | |
| Infusion related reaction | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 7 | | |
| Procedural haemorrhage | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Procedural pain | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Skin laceration | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 3 | | |
| Stoma site erythema | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Wound dehiscence | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Cardiac disorders | | | |
| Bradycardia | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Cardiac disorder | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Palpitations | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| Supraventricular extrasystoles | | | |

| | | | |
|-------------------------------|-------------------|--|--|
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Tachycardia | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 5 | | |
| Nervous system disorders | | | |
| Autonomic neuropathy | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Balance disorder | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Dizziness | | | |
| subjects affected / exposed | 27 / 149 (18.12%) | | |
| occurrences (all) | 33 | | |
| Dysaesthesia | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Dysgeusia | | | |
| subjects affected / exposed | 11 / 149 (7.38%) | | |
| occurrences (all) | 17 | | |
| Headache | | | |
| subjects affected / exposed | 22 / 149 (14.77%) | | |
| occurrences (all) | 26 | | |
| Hypoaesthesia | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 4 | | |
| Neuropathy peripheral | | | |
| subjects affected / exposed | 22 / 149 (14.77%) | | |
| occurrences (all) | 25 | | |
| Paraesthesia | | | |
| subjects affected / exposed | 9 / 149 (6.04%) | | |
| occurrences (all) | 9 | | |
| Peripheral sensory neuropathy | | | |
| subjects affected / exposed | 27 / 149 (18.12%) | | |
| occurrences (all) | 30 | | |

| | | | |
|--------------------------------------|-------------------|--|--|
| Somnolence | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Syncope | | | |
| subjects affected / exposed | 6 / 149 (4.03%) | | |
| occurrences (all) | 7 | | |
| Taste disorder | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| Tremor | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 64 / 149 (42.95%) | | |
| occurrences (all) | 88 | | |
| Leukocytosis | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 6 | | |
| Leukopenia | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 5 | | |
| Neutropenia | | | |
| subjects affected / exposed | 28 / 149 (18.79%) | | |
| occurrences (all) | 52 | | |
| Normocytic anaemia | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 15 / 149 (10.07%) | | |
| occurrences (all) | 22 | | |
| Ear and labyrinth disorders | | | |
| Deafness | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Tinnitus | | | |

| | | | |
|--------------------------------|-------------------|--|--|
| subjects affected / exposed | 10 / 149 (6.71%) | | |
| occurrences (all) | 10 | | |
| Eye disorders | | | |
| Foreign body sensation in eyes | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Glaucoma | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Retinopathy | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Vision blurred | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 4 | | |
| Vitreous floaters | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 4 | | |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 5 | | |
| Abdominal distension | | | |
| subjects affected / exposed | 14 / 149 (9.40%) | | |
| occurrences (all) | 17 | | |
| Abdominal pain | | | |
| subjects affected / exposed | 35 / 149 (23.49%) | | |
| occurrences (all) | 50 | | |
| Abdominal pain lower | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 5 | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 12 / 149 (8.05%) | | |
| occurrences (all) | 15 | | |
| Ascites | | | |

| | | | |
|------------------------------------|-------------------|--|--|
| subjects affected / exposed | 13 / 149 (8.72%) | | |
| occurrences (all) | 18 | | |
| Cheilitis | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 4 | | |
| Constipation | | | |
| subjects affected / exposed | 41 / 149 (27.52%) | | |
| occurrences (all) | 53 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 45 / 149 (30.20%) | | |
| occurrences (all) | 67 | | |
| Dry mouth | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 4 | | |
| Dyspepsia | | | |
| subjects affected / exposed | 9 / 149 (6.04%) | | |
| occurrences (all) | 10 | | |
| Dysphagia | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 5 | | |
| Faeces soft | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Gastrointestinal disorder | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 2 | | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 9 / 149 (6.04%) | | |
| occurrences (all) | 9 | | |
| Glossodynia | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Haemorrhoids | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 4 | | |
| Lower gastrointestinal haemorrhage | | | |

| | | | |
|----------------------------------------|-------------------|--|--|
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Nausea | | | |
| subjects affected / exposed | 67 / 149 (44.97%) | | |
| occurrences (all) | 114 | | |
| Oesophagitis | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Proctalgia | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Retching | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Stomatitis | | | |
| subjects affected / exposed | 21 / 149 (14.09%) | | |
| occurrences (all) | 23 | | |
| Vomiting | | | |
| subjects affected / exposed | 45 / 149 (30.20%) | | |
| occurrences (all) | 72 | | |
| Skin and subcutaneous tissue disorders | | | |
| Alopecia | | | |
| subjects affected / exposed | 24 / 149 (16.11%) | | |
| occurrences (all) | 26 | | |
| Dermatitis acneiform | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Drug eruption | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Dry skin | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 4 | | |

| | | | |
|-----------------------------|------------------|--|--|
| Hyperhidrosis | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 7 | | |
| Nail disorder | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 6 | | |
| Photosensitivity reaction | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Pruritus | | | |
| subjects affected / exposed | 10 / 149 (6.71%) | | |
| occurrences (all) | 14 | | |
| Rash maculo-papular | | | |
| subjects affected / exposed | 12 / 149 (8.05%) | | |
| occurrences (all) | 16 | | |
| Rash | | | |
| subjects affected / exposed | 14 / 149 (9.40%) | | |
| occurrences (all) | 14 | | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 5 | | |
| Dysuria | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 6 | | |
| Haematuria | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 6 | | |
| Proteinuria | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Renal failure | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 2 | | |
| Endocrine disorders | | | |

| | | | |
|-------------------------------------------------|-------------------|--|--|
| Hyperthyroidism | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 3 | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 6 / 149 (4.03%) | | |
| occurrences (all) | 7 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 24 / 149 (16.11%) | | |
| occurrences (all) | 28 | | |
| Back pain | | | |
| subjects affected / exposed | 25 / 149 (16.78%) | | |
| occurrences (all) | 33 | | |
| Groin pain | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Limb discomfort | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Myalgia | | | |
| subjects affected / exposed | 12 / 149 (8.05%) | | |
| occurrences (all) | 14 | | |
| Muscular weakness | | | |
| subjects affected / exposed | 6 / 149 (4.03%) | | |
| occurrences (all) | 10 | | |
| Muscle spasms | | | |
| subjects affected / exposed | 14 / 149 (9.40%) | | |
| occurrences (all) | 17 | | |
| Neck pain | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 5 | | |
| Osteonecrosis of jaw | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Pain in extremity | | | |

| | | | |
|-----------------------------------|------------------|--|--|
| subjects affected / exposed | 10 / 149 (6.71%) | | |
| occurrences (all) | 10 | | |
| Sacral pain | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Infections and infestations | | | |
| Biliary tract infection | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Cellulitis | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 4 | | |
| Conjunctivitis | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Ear infection | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Enterocolitis infectious | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Herpes zoster | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Infection | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Lip infection | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 6 | | |

| | | | |
|-----------------------------------------|-------------------|--|--|
| Oral herpes | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| Oral candidiasis | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| Peritonitis | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Rhinitis | | | |
| subjects affected / exposed | 5 / 149 (3.36%) | | |
| occurrences (all) | 5 | | |
| Skin infection | | | |
| subjects affected / exposed | 4 / 149 (2.68%) | | |
| occurrences (all) | 4 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 17 / 149 (11.41%) | | |
| occurrences (all) | 20 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 13 / 149 (8.72%) | | |
| occurrences (all) | 23 | | |
| Viral upper respiratory tract infection | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 37 / 149 (24.83%) | | |
| occurrences (all) | 45 | | |
| Dehydration | | | |
| subjects affected / exposed | 14 / 149 (9.40%) | | |
| occurrences (all) | 18 | | |
| Food intolerance | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Hypercholesterolaemia | | | |

| | | | |
|-----------------------------|-------------------|--|--|
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Hypercalcaemia | | | |
| subjects affected / exposed | 1 / 149 (0.67%) | | |
| occurrences (all) | 1 | | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 13 / 149 (8.72%) | | |
| occurrences (all) | 23 | | |
| Hypernatraemia | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |
| Hyperkalaemia | | | |
| subjects affected / exposed | 9 / 149 (6.04%) | | |
| occurrences (all) | 11 | | |
| Hypertriglyceridaemia | | | |
| subjects affected / exposed | 6 / 149 (4.03%) | | |
| occurrences (all) | 9 | | |
| Hyperuricaemia | | | |
| subjects affected / exposed | 6 / 149 (4.03%) | | |
| occurrences (all) | 6 | | |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 14 / 149 (9.40%) | | |
| occurrences (all) | 18 | | |
| Hypocalcaemia | | | |
| subjects affected / exposed | 13 / 149 (8.72%) | | |
| occurrences (all) | 15 | | |
| Hypoglycaemia | | | |
| subjects affected / exposed | 3 / 149 (2.01%) | | |
| occurrences (all) | 3 | | |
| Hypokalaemia | | | |
| subjects affected / exposed | 15 / 149 (10.07%) | | |
| occurrences (all) | 22 | | |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 11 / 149 (7.38%) | | |
| occurrences (all) | 11 | | |
| Hyponatraemia | | | |

| | | | |
|-----------------------------|-------------------|--|--|
| subjects affected / exposed | 16 / 149 (10.74%) | | |
| occurrences (all) | 25 | | |
| Hypophosphataemia | | | |
| subjects affected / exposed | 7 / 149 (4.70%) | | |
| occurrences (all) | 7 | | |
| Vitamin D deficiency | | | |
| subjects affected / exposed | 2 / 149 (1.34%) | | |
| occurrences (all) | 2 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31 October 2017 | The primary purpose of this amendment was to address changes requested by the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. |
| 27 September 2018 | The primary purpose of this amendment was to update the inclusion criteria for the microsatellite stable colorectal cancer (MSS-CRC) expansion cohort. |
| 17 May 2019 | The primary purpose of this amendment was to change the study drug formulation. |
| 09 December 2020 | The primary purpose of this amendment was to provide guidance for the management of ongoing participants, as enrollment was complete and sufficient data had been collected for primary and secondary endpoint analysis. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported